<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Ther Adv Neurol Disord</journal-id>
<journal-id journal-id-type="iso-abbrev">Ther Adv Neurol Disord</journal-id>
<journal-id journal-id-type="publisher-id">TAN</journal-id>
<journal-id journal-id-type="hwp">sptan</journal-id>
<journal-title-group>
<journal-title>Therapeutic Advances in Neurological Disorders</journal-title>
</journal-title-group>
<issn pub-type="ppub">1756-2856</issn>
<issn pub-type="epub">1756-2864</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31105770</article-id>
<article-id pub-id-type="pmc">6503605</article-id>
<article-id pub-id-type="doi">10.1177/1756286419845567</article-id>
<article-id pub-id-type="publisher-id">10.1177_1756286419845567</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Advances in Neuroimaging</subject>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Advances in imaging of brain abnormalities in neuromuscular
disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-9554-8794</contrib-id>
<name>
<surname>Angelini</surname>
<given-names>Corrado</given-names>
</name>
<xref ref-type="corresp" rid="corresp1-1756286419845567"></xref>
<aff id="aff1-1756286419845567">Fondazione Ospedale San Camillo IRCCS, Via
Alberoni 70, Venezia, 30126, Italia</aff>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pinzan</surname>
<given-names>Elena</given-names>
</name>
<aff id="aff2-1756286419845567">Fondazione Ospedale San Camillo IRCCS, Venezia,
Italia</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-1756286419845567">
<email>corrado.angelini@ospedalesancamillo.net</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>06</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<volume>12</volume>
<elocation-id>1756286419845567</elocation-id>
<history>
<date date-type="received">
<day>6</day>
<month>8</month>
<year>2018</year>
</date>
<date date-type="accepted">
<day>5</day>
<month>3</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2019</copyright-statement>
<copyright-year>2019</copyright-year>
<copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder>
<license license-type="creative-commons" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">
<license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="http://www.creativecommons.org/licenses/by-nc/4.0/">http://www.creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Brain atrophy, white matter abnormalities, and ventricular enlargement have been
described in different neuromuscular diseases (NMDs). We aimed to provide a
comprehensive overview of the substantial advancement of brain imaging in
neuromuscular diseases by consulting the main libraries (<italic>Pubmed,
Scopus</italic> and <italic>Google Scholar</italic>) including the more
common forms of muscular dystrophies such as dystrophinopathies,
dystroglycanopathies, myotonic dystrophies, facioscapulohumeral dystrophy,
limb-girdle muscular dystrophy, congenital myotonia, and congenital myopathies.
A consistent, widespread cortical and subcortical involvement of grey and white
matter was found. Abnormalities in the functional connectivity in brain networks
and metabolic alterations were observed with positron emission tomography (PET)
and single photon emission computed tomography (SPECT). Pathological brain
changes with cognitive dysfunction seemed to be frequently associated in NMDs.
In particular, in congenital muscular dystrophies (CMDs), skeletal muscular
weakness, severe hypotonia, WM abnormalities, ventricular dilatation and
abnormalities in cerebral gyration were observed.</p>
<p>In dystroglycanopathy 2I subtype (LGMD2I), adult patients showed subcortical
atrophy and a WM periventricular involvement, moderate ventriculomegaly, and
enlargement of subarachnoid spaces. Correlations with clinical features have
been observed with brain imaging characteristics and alterations were prominent
in congenital or childhood onset cases. In myotonic dystrophy type 2 (DM2)
symptoms seem to be less severe than in type 1 (DM1).</p>
<p>In Duchenne and Becker muscular dystrophies (DMD, BMD) cortical atrophy is
associated with minimal ventricular dilatation and WM abnormalities.</p>
<p>Late-onset glycogenosis type II (GSD II) or Pompe infantile forms are
characterized by delayed myelination. Only in a few cases of oculopharyngeal
muscular dystrophy (OPMD) central nervous system involvement has been described
and associated with executive functions impairment.</p>
</abstract>
<kwd-group>
<kwd>brain</kwd>
<kwd>imaging</kwd>
<kwd>MRI</kwd>
<kwd>muscular dystrophy</kwd>
</kwd-group>
<funding-group>
<award-group id="award1-1756286419845567">
<funding-source id="funding1-1756286419845567">
<institution-wrap>
<institution>Telethon</institution>
<institution-id></institution-id>
</institution-wrap>
</funding-source>
<award-id rid="funding1-1756286419845567">GGP14066</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January-December 2019</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="section1-1756286419845567" sec-type="intro">
<title>Introduction</title>
<p>The interest in brain imaging of inherited neuromuscular disorders has increased in
recent years. Several brain imaging studies on neuromuscular diseases (NMDs) have
been published to consider both muscular impairment and central nervous system (CNS) involvement.<sup><xref ref-type="bibr" rid="bibr1-1756286419845567">1</xref></sup> In the past three decades, researchers have started to focus not only on
genetic, biopsy, or muscular imaging biomarkers but also on brain involvement. To
date, information on brain involvement in ‘less rare’ and best-known inherited
pathologies such as myotonic dystrophies, type 1 (DM1), and type 2 (DM2) are
available, while for other NMDs (i.e. facioscapulohumeral dystrophy) CNS involvement
needs to be investigated. Nevertheless, the origin and spatiotemporal evolution of
CNS involvement, as well as their correlation with neuropsychological and clinical
features, still remain unclear. Correlations between brain neuroimaging parameters
and clinical symptoms have been reported in different studies but results are often
difficult to replicate. This might be related to small sample sizes or heterogeneity
in the phenotypes assessed. Moreover, we have to consider that clinical
symptomatology might not be linked to specific brain alterations but more probably
to dysfunctional networks. In particular, brain imaging studies have been improved
by the development of more sophisticated technologies and experimental paradigms.
Several imaging methods have been applied to detect brain involvement in patients
affected by NMDs, including structural and functional, such as cranial computed
tomography (CT), magnetic resonance imaging (MRI), single photon emission computed
tomography (SPECT), positron emission tomography (PET), and recently, ultrasound.
After the first CT scans, more advanced MRI techniques were applied: morphological
to examine the brain structure or functional to investigate brain network activity,
cerebral glucose metabolism, or perfusion. The new application of ultrasound
(transcranial B-mode sonography) allowed the examination of <italic>in vivo</italic>
brain structural integrity, making easier to evaluate CNS disorders in congenital
forms and neonatology patients. The fact that brain examination is expensive and not
easy to conduct in young or claustrophobic patients, or in the case of respiratory
insufficiency, has to be considered. For this reason, all these limitations have
required the application of noninvasive, easily performed investigation techniques
(i.e. transcranial B-mode sonography or arterial spin labeling), especially in
children.</p>
<p>Brain involvement in NMDs has been well described and proved to be clinically
relevant. Several MRI studies revealed a wide spectrum of brain abnormalities,
including diffused grey matter (GM) and white matter (WM) abnormalities and
ventricular enlargement.</p>
<p>This review is based on papers reporting neuroimaging results on NMDs. Scientific
papers were searched from 1980 to May 2018 on the main databases (<italic>PubMed,
MedLine, Google Scholar</italic>). We included only free and full available
texts written in English. We excluded papers concerning pharmacological trials. The
temporal interval of 1980–2018 was selected in order to include all the information
regarding some conditions [i.e. congenital muscular dystrophies (CMDs)]; while the
number of studies on muscular dystrophies has increased in recent decades,
consistent reports are still missing for other NMDs. We considered the papers on the
following NMDs: dystrophinopathies, dystroglycanopathies, myotonic dystrophies,
facioscapulohumeral dystrophy, limb-girdle muscular dystrophies, congenital
myotonias, congenital myopathies, and related terms or abbreviations. We included
the following imaging techniques in the research: ‘computed tomography’ or ‘CT’,
‘magnetic resonance imaging’ or ‘MRI’, ‘single photon emission computed tomography’
or ‘SPECT’, ‘positron emission tomography’ or ‘PET’, ultrasound, ‘transcranial
sonography’ or ‘TCS’. We included only those papers containing information about
brain involvement.</p>
<p>The total number of papers found in 38 years (1980–2018) on brain imaging was
246.</p>
<p>Considering our inclusion criteria, that excluded single cases, pharmaceutical trials
and papers appearing more than one time in the search, we included a final number of
89 articles in this review.</p>
</sec>
<sec id="section2-1756286419845567">
<title>Brain imaging techniques</title>
<p>Brain involvement has been studied in NMDs using both quantitative and
nonquantitative techniques that analyzed the morphological structure and functional
activity. At the beginning of the 1980s cranial studies, using conventional CT were
performed and MRI-descriptive and conventional investigations were conducted to
assess WM and GM abnormalities. Conventional morphological brain investigations
allowed the description and quantification of morphological features (i.e. WM
changes). These were rater-dependent and made results more controversial and less
uniform to reproduce. Qualitative scales have been created to grade the severity and
location of WM lesions (WMLs) using visual rating scales (i.e. Fazekas or Wahlund
scale) on T2-weighted or fluid-attenuated inversion recovery (FLAIR) sequences. In
particular, age-related WM changes (ARWMCs) has been proved to be a valid
qualitative scale to grade lesions in dystrophies. Ranging from 0 (no lesion) to 3
(diffuse involvement) it allowed the assessment of four different areas separated
for each hemisphere.<sup><xref ref-type="bibr" rid="bibr2-1756286419845567">2</xref></sup></p>
<p>The recent technological advances introduced more sophisticated techniques and
experimental paradigms of study. Through quantitative analysis results became more
reproducible, allowing quantification of more complex and specific brain
proprieties. For this reason, the number of nonquantitative conventional
morphological brain MRI studies decreased due to the development of observed
independent techniques [i.e. voxel-based morphometry (VBM), diffusion tensor imaging
(DTI), functional MRI (fMRI)]. At a macro-structural level <italic>via</italic>
brain parenchymal fraction (BPF) methods, global brain atrophy can be quantified.
VBM estimates the local amount of a specific tissue. Using the automatic
classification of T1-weighted images VBM leads to extract, for each voxel GM, WM,
and cerebrospinal fluid and compare tissues probability maps of global density (or
regional volume) for each part. VBM investigation can be used to estimate clusters
of focal cortical or subcortical alteration (mainly GM) comparing different groups.<sup><xref ref-type="bibr" rid="bibr3-1756286419845567">3</xref></sup></p>
<p>Whole brain volume or regions of interest (ROIs) can be calculated to detect changes
in density. Recently, surface-based analysis addressed structural information about
the morphological organization of GM volumes. The surface-based morphometry allows
the assessment of the cortex surface and extraction of different parameters (i.e.
cortical thickness, surface area, cortical folding, and gyrification or any
combination of them). Cortical thickness is a measure of the amount of GM estimated
at each point on the cortex. It may be employed to detect pathological changes
associated with the disease process. Contiguous maps of cortical thickness can be
generated and carefully used as a marker of the integrity of the cerebral cortex,
related to the size, number, and density of cells.<sup><xref ref-type="bibr" rid="bibr4-1756286419845567">4</xref></sup> The DTI technique quantifies (<italic>in vivo</italic>) WM microstructures
analyzing the magnitude and directionality of diffusivity proprieties of water
molecules in tissues. Some pathological conditions can alter the diffusion
proprieties of water in the fiber tracts reducing, for example, the anisotropic
propriety of water molecules within the WM. DTI is a variant of MRI used to map the
diffusion process and identify changes in organization in the WM microstructure,
such as fiber density and WM integrity;<sup><xref ref-type="bibr" rid="bibr5-1756286419845567">5</xref></sup> extracting several parameters could be used to investigate different
properties. Fractional anisotropy (FA) is an indirect measure of the directionality
and coherence of fibers. A lower FA shows a reduction in the density of WM, a loss
of structural organization (axonal bundle coherence), or a variation in membrane
permeability to water.<sup><xref ref-type="bibr" rid="bibr6-1756286419845567">6</xref></sup> Mean diffusivity measures the overall magnitude of water diffusion without
any directional information. Other parameters such as the diffusivity along the
principal axis (AD) and the average of the diffusivities along the two minor axes
(RD) allow evaluation of the structural damage. The first could reflect axonal
pathological changes, the second could be more related to demyelination and axonal
membranes alteration.<sup><xref ref-type="bibr" rid="bibr7-1756286419845567">7</xref></sup></p>
<p>Functional brain imaging techniques attempt to measure neuronal activity by detecting
changes in metabolism (the metabolic activity of oxygen or glucose in different
tissues). fMRI is used to study cerebral activity indirectly.<sup><xref ref-type="bibr" rid="bibr8-1756286419845567">8</xref></sup> It measures the difference in magnetization between oxygen-rich and
oxygen-poor blood in different tissue and is based on the linkage between cerebral
blood flow (CBF) and neuronal activation. Oxygen consumption is higher during neural
activation and, to meet this growth of demand, increased CBF is needed for the
active brain cells. The blood-oxygen-level-dependent (BOLD) signal is related to the
level of energy used by neurons due to changing O<sub>2</sub> in the blood.<sup><xref ref-type="bibr" rid="bibr9-1756286419845567">9</xref></sup></p>
<p>Spontaneous fluctuation of the BOLD signal is present even without any experimental
paradigm or any other explicit input. In fact, fMRI examination can be performed
during a specific task or by a resting-state fMRI (rs-fMRI) detecting the
spontaneous variance of the BOLD signal. Task-based fMRI is used to identify regions
that are functionally involved during a specific task performance. The rs-fMRI is
used to explore the brain circuits and identify functionally connected neural
networks (i.e. default mode network).<sup><xref ref-type="bibr" rid="bibr10-1756286419845567">10</xref></sup></p>
<p>Other functional techniques that are based on brain hemodynamic include SPECT and PET.<sup><xref ref-type="bibr" rid="bibr11-1756286419845567">11</xref></sup> SPECT generates tomographic images of the three-dimensional (3D) distribution
of a specific radiopharmaceutical and can directly display measures of regional
brain hemodynamics (i.e. <sup><xref ref-type="bibr" rid="bibr133-1756286419845567">133</xref></sup>xenon) affording whole brain coverage. Moreover, regional Cerebral Blood Flow
(rCBF) maps can be obtained by SPECT in order to outline the regions with abnormal perfusion.<sup><xref ref-type="bibr" rid="bibr12-1756286419845567">12</xref></sup></p>
<p>PET imaging provides <italic>in vivo</italic> quantitative measures of CBF with the
injection of radioactive tracers, such as fluorodeoxyglucose (FDG)-PET that allow
the assessment of neuronal glucose metabolism. Using different tracers, PET
describes the metabolic activity of glucose in tissues with a positron and emitting
radioisotopes. According to neuronal metabolic activity, it indirectly assesses the
mental activity corresponding to glucose uptake. Recently, transcranial sonography
(TCS) has been used in childhood NMDs. TCS is a well-established diagnostic method
mainly used to assess extrapyramidal movement disorders in neurological disease. It
started to be used to study structural CNS changes in NMDs. It is a noninvasive tool
that provides reliable additional information about hyperechogenicity of the CNS
based on the increasing amounts of iron, bound to proteins other than ferritin.<sup><xref ref-type="bibr" rid="bibr13-1756286419845567">13</xref></sup> All the brain imaging techniques described above have their own advantages in
specific clinical settings, leading to improved knowledge about the morphological
and functional activity in the brain of patients in different clinical conditions
(<xref ref-type="table" rid="table1-1756286419845567">Table 1</xref>).</p>
<table-wrap id="table1-1756286419845567" orientation="portrait" position="float">
<label>Table 1.</label>
<caption>
<p>Comparison of neuroimaging techniques used in various neuromuscular
disorders.</p>
</caption>
<alternatives>
<graphic xlink:href="10.1177_1756286419845567-table1"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Neuromuscular diseases</th>
<th align="left" colspan="6" rowspan="1">Technique<hr/></th>
</tr>
<tr>
<th colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1">CT</th>
<th align="left" colspan="1" rowspan="1">MRI</th>
<th align="left" colspan="1" rowspan="1">fMRI</th>
<th align="left" colspan="1" rowspan="1">SPECT</th>
<th align="left" colspan="1" rowspan="1">PET</th>
<th align="left" colspan="1" rowspan="1">TCS</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">Dystroglycanopathies</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">++</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Congenital muscular dystrophies</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">++</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Myotonic dystrophy type 1</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">++</td>
<td colspan="1" rowspan="1">++</td>
<td colspan="1" rowspan="1">++</td>
<td colspan="1" rowspan="1">++</td>
<td colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Myotonic dystrophy type 2</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">++</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Dystrophinopathies</td>
<td colspan="1" rowspan="1">++</td>
<td colspan="1" rowspan="1">++</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Glycogenosis disease type II</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Oculopharyngeal muscular dystrophy</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Facioscapulohumeral dystrophy</td>
<td colspan="1" rowspan="1">±</td>
<td colspan="1" rowspan="1">+</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
<td colspan="1" rowspan="1">−</td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="table-fn1-1756286419845567">
<p>Changes: −, not described or reported; ±, slight brain changes; +,
significant brain changes; ++, marked structural or functional
abnormality.</p>
</fn>
<fn id="table-fn2-1756286419845567">
<p>CT, computerized tomography; fMRI, functional MRI; MRI, magnetic
resonance imaging; PET, positron emission tomography; SPECT, single
photon emission computed tomography; TCS, transcranial sonography.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section3-1756286419845567">
<title>Neuromuscular disease with brain involvement</title>
<p>Neuromuscular disorders are a group of heterogeneous, hereditary, genetic, or
acquired diseases affecting mainly skeletal muscle. Major advances in molecular
genetic research led to discovering the pathogenic determinant of the
dystrophinopathies in the 1980s. Later, an increased number of genes have been found
to be associated with different forms of muscular dystrophy. This led to the
classification of them in terms of molecular and genetic features (genes and
functions of the respective proteins affected) rather than on clinical symptoms
(clinical pattern of weakness, mode of inheritance, and age of onset).<sup><xref ref-type="bibr" rid="bibr14-1756286419845567">14</xref></sup> The main categories of inherited neuromuscular diseases are neuropathies
(diseases of a peripheral nerve), myopathies, motor neuron diseases, and muscular
dystrophies. Not so long ago, muscular dystrophies were mainly divided into six
categories such as Duchenne muscular dystrophy (DMD) and Becker muscular dystrophy,
limb-girdle muscular dystrophy (LGMD), distal myopathies, CMDs, facioscapulohumeral
muscular dystrophy and myotonic dystrophies. Genetic investigations have expanded
our knowledge in muscular dystrophies and now more than 50 forms of NMDs have been
identified on molecular bases, each one with different clinical features (e.g.
muscle pattern of involvement, variable course different genotype–phenotype correlation).<sup><xref ref-type="bibr" rid="bibr15-1756286419845567">15</xref></sup> In recent years next-generation sequencing technology has led to the
discovery of novel causative genes and differentiation of novel myopathies.<sup><xref ref-type="bibr" rid="bibr16-1756286419845567">16</xref></sup> Brain involvement has been reported in different types of NMDs. Recently,
neuromuscular conditions have started to be considered even for their multisystemic
features and for the implications they have on CNS, such as myotonic dystrophies,
dystroglycanopathies and glycogenosis disease type II. The genotype/phenotype
correlation remains controversial considering the wide variability of clinical
expression. Nevertheless, although rare, correlations between genotype and phenotype
have been established but further investigations are needed.<sup><xref ref-type="bibr" rid="bibr17-1756286419845567">17</xref><xref ref-type="bibr" rid="bibr18-1756286419845567"></xref><xref ref-type="bibr" rid="bibr19-1756286419845567"></xref>–<xref ref-type="bibr" rid="bibr20-1756286419845567">20</xref></sup></p>
</sec>
<sec id="section4-1756286419845567">
<title>Dystroglycanopathies</title>
<p>Dystroglycanopathies are a group of autosomal recessive conditions characterized by
reduced glycosylation of α-dystroglycan (α-DG). Clinical manifestations are
extremely variable, and a wide spectrum of phenotypic outcomes has been identified.
A different pattern of disability symptomatology has been reported: from the more
severe congenital form of Walker Warburg syndrome (WWS) to the milder adult-onset
form of LGMD. WWS is characterized by a severe brain involvement (see below
congenital forms description). The adult-onset form of LGMD may not present brain or
eye involvement.<sup><xref ref-type="bibr" rid="bibr21-1756286419845567">21</xref></sup> There are many LGMD subtypes (i.e. sarcoglycanopathy, calpainopathy,
dysferlinopathy). Commonly, type 1 (i.e. LGMD1A, LGMD1B) refers to genetic types
showing dominant inheritance (requiring one mutation for symptoms to result). Type 2
refers to recessive inheritance (requiring two mutations from each parent for
symptoms to result).<sup><xref ref-type="bibr" rid="bibr22-1756286419845567">22</xref></sup> Unfortunately, only a few studies have analyzed brain involvement in
LGMD.</p>
<p>Dystroglycanopathies 2I subtype (LGMD2I) is due to the mutation of the
fukutin-related protein (FKRP) gene. It is characterized by a mild to severe
phenotype with prominent skeletal muscle involvement. Bourteel and colleagues
assessed 11 French patients with LGMD2I (FKRP) mutation.<sup><xref ref-type="bibr" rid="bibr23-1756286419845567">23</xref></sup> They underwent clinical, neuropsychological, and brain MRI investigation.
Myocardiopathy and respiratory insufficiency were preponderant. Memory impairment
was detected in four patients. Subcortical atrophy and a WM periventricular
involvement were associated with changes in α-DG expression in brain.<sup><xref ref-type="bibr" rid="bibr23-1756286419845567">23</xref></sup> A second study, with a smaller sample size of 10 patients with LGMD2I, showed
heterogeneous results characterized by nonspecific WM abnormalities, moderate
ventriculomegaly, and enlargement of subarachnoid spaces. In one patient, cerebellar
atrophy was detected. Neuropsychological evaluation showed a deficit in executive
functions and visuospatial abilities without effects on intelligent quotient (IQ)
score. In this case, Authors argued that abnormal glycosylation of α-DG in LGMD2I
might affect brain development and cognitive performance. Frontal and parietal lobes
would be mainly involved even though there was not a specific MRI pattern.</p>
<p>A study performed on five patients affected by LGMD due to LAMA2 mutations by
Gavassini and colleagues showed various degrees of CNS involvement with widespread
brain WM hyperintensities.<sup><xref ref-type="bibr" rid="bibr24-1756286419845567">24</xref></sup> A mild deficit in executive functions and low IQ scores were noted in three
patients. Interestingly, in one patient brain MRI abnormalities preceded the
clinical onset of muscle weakness. So, authors argued that WM abnormalities were
always present and could be considered a diagnostic criterion for LGMD associated
with LAMA2 mutations. Only one study on LGMD2M reported normal brain MRI and
cognitive functioning.<sup><xref ref-type="bibr" rid="bibr25-1756286419845567">25</xref></sup></p>
<p>Detailed knowledge about other LGMDs disease forms is lacking (i.e. LGMD type 2N;
LGMD2N). LGMD2N is due to mutations in the <italic>POMT2</italic> gene. It is
characterized by wasting and weakness of the muscles in the shoulder and hip region.
Østergaard and colleagues performed a brain MRI study in 10 patients.<sup><xref ref-type="bibr" rid="bibr26-1756286419845567">26</xref></sup> They respectively showed abnormality in 3 of the 10 patients in brain imaging
evaluation. They found mild ventricular enlargement due to central and cortical
atrophy, periventricular hyperintensities, and frontal atrophy of the left
hemisphere in the last cases. MRI abnormalities were associated with lower
Mini-Mental State Examination (MMSE) scores, suggesting a link with cognitive
impairment. Finally, in LGMD2K (<italic>POMT1</italic>), intellectual disability
with low IQ without structural brain abnormalities Were reported in all
patients.<sup><xref ref-type="bibr" rid="bibr27-1756286419845567">27</xref>,<xref ref-type="bibr" rid="bibr28-1756286419845567">28</xref></sup></p>
</sec>
<sec id="section5-1756286419845567">
<title>Congenital muscular dystrophies</title>
<p>CMDs are a group of muscular disorders characterized by an early onset of skeletal
muscular weakness (within 1 year of age), severe hypotonia, with a variable
involvement of organs, such as the brain, and characterized by different outcomes.
The prevalence of CMDs is not well established. Several classifications of CMDs are
reported in the literature.<sup><xref ref-type="bibr" rid="bibr29-1756286419845567">29</xref>,<xref ref-type="bibr" rid="bibr30-1756286419845567">30</xref></sup> Based on the combination of clinical, biochemical, molecular,
and genetic findings, Voit and Tomè (2004) distinguished CMDs into four groups:
Merosinopathy deficit of lamin α2 or ‘merosin’; dystroglycanopathies caused by
glycosylation of α-DG abnormality including WWS, muscle-eye-brain diseases (MEBs),
Fukuyama CMD (FCMD), and MDC1B, MDC1C, MDC1D; rigid spine syndrome; Ullrich
dystrophy; and primary or secondary α7 integrin deficiency.<sup><xref ref-type="bibr" rid="bibr31-1756286419845567">31</xref></sup></p>
<p>Here, we will mainly focus on congenital dystroglycanopathies (FCMD, MEBs, and WWS
diseases) as the literature is more plentiful and the clinical manifestations are
more evident.<sup><xref ref-type="bibr" rid="bibr31-1756286419845567">31</xref></sup> Notably, clinical variability is shown among CMDs forms, sometimes through
subclinical appearance. Brain involvement is frequent in CMDs and is the main
feature in WWS and MEBs, subtypes of CMD, with a prevalent involvement of ocular structures.<sup><xref ref-type="bibr" rid="bibr32-1756286419845567">32</xref></sup></p>
<p>The FCMD type is characterized by a progressive muscular deficit, mental retardation
and speech disorders associated with a plain brain involvement. CT examination
performed on 22 patients revealed WM abnormalities, ventricular dilatation, cortical
sulci, longitudinal cerebral fissure, and Sylvian fissure alterations.<sup><xref ref-type="bibr" rid="bibr33-1756286419845567">33</xref></sup> Abnormalities in cerebral gyration are frequent. Micropolygyria of the
cerebrum and cerebellum with loss of cytoarchitecture has been detected using brain
MRIs in patients with FCMD.<sup><xref ref-type="bibr" rid="bibr34-1756286419845567">34</xref></sup> In addition, brain MRI shows WM abnormalities, cobblestone occipital cortex,
and cerebellar abnormalities.<sup><xref ref-type="bibr" rid="bibr33-1756286419845567">33</xref>,<xref ref-type="bibr" rid="bibr35-1756286419845567">35</xref></sup> Nevertheless, the initial WM
involvement seems to not progress or change over time.<sup><xref ref-type="bibr" rid="bibr36-1756286419845567">36</xref></sup> MEB disease is characterized by brain malformation, with a cortical defective
migration dysfunction, WM abnormalities, and anomalies of the brainstem and cerebellum.<sup><xref ref-type="bibr" rid="bibr37-1756286419845567">37</xref></sup> Recently Yiş and colleagues detected WM abnormalities, ventriculomegaly, and
multiple cerebellar cysts in a cohort of 34 patients.<sup><xref ref-type="bibr" rid="bibr38-1756286419845567">38</xref></sup> Others reported cortical gyration abnormalities at the frontal level,
microcystic degeneration, and polymicrogyria of the temporal lobe associated with
cognitive deficits in 13-year-old girl with long-term survival.<sup><xref ref-type="bibr" rid="bibr15-1756286419845567">15</xref></sup></p>
<p>The brain structural MRI pattern in MEB CMDs is similar to that reported for patients
with FCMD, with lissencephaly type II/pachygyria, brain stem, and cerebellar
abnormalities. WWS is the most severe form of CMD with an evident involvement of
muscles, ocular system, and CNS, and is associated with mental retardation. It is a
severe disorder and children do not survive more than 1 year. It is characterized by
clinical malformation featuring ‘cobblestone lissencephaly’ cortex, ventricular
enlargement, obstructive hydrocephalus, neuronal heterotopias, agyria,
polymicrogyria, corpus callosum agenesis, and diffuse WM changes as shown in brain
MRI examination.<sup><xref ref-type="bibr" rid="bibr15-1756286419845567">15</xref>,<xref ref-type="bibr" rid="bibr39-1756286419845567">39</xref>,<xref ref-type="bibr" rid="bibr40-1756286419845567">40</xref></sup></p>
</sec>
<sec id="section6-1756286419845567">
<title>Myotonic dystrophy type 1: Steinert’s disease</title>
<p>DM1 is an autosomal dominant inheritance, multisystemic disorders. It is the most
prevalent muscular dystrophy; occurring in 1:8000 people worldwide.<sup><xref ref-type="bibr" rid="bibr41-1756286419845567">41</xref></sup> Muscular, cardiac, endocrine, ocular, hormonal, and neurological systems are
involved in the disease on variable levels.<sup><xref ref-type="bibr" rid="bibr42-1756286419845567">42</xref></sup> The Cytosine-Thymine-Guanine (CTG) expansion size seems to be directly
correlated to the age of onset (inverse correlation) and to a more severe clinical
phenotype (positive correlation).<sup><xref ref-type="bibr" rid="bibr43-1756286419845567">43</xref></sup> DM1 can be divided into four subtypes based on CTG repeat sizes and onset of
symptoms, each one associated with specific clinical features: (1) congenital
(CDM1); (2) childhood onset, or infantile and juvenile form (JDM1); (3) adult onset;
and (4) late onset/asymptomatic.<sup><xref ref-type="bibr" rid="bibr42-1756286419845567">42</xref>,<xref ref-type="bibr" rid="bibr44-1756286419845567">44</xref></sup> CNS involvement in DM1 is
commonly observed but characterized by between-study heterogeneity.<sup><xref ref-type="bibr" rid="bibr45-1756286419845567">45</xref></sup> Higher impairment has been seen in patients with early onset.<sup><xref ref-type="bibr" rid="bibr46-1756286419845567">46</xref>,<xref ref-type="bibr" rid="bibr47-1756286419845567">47</xref></sup> Congenital and
juvenile forms are the most severe characterized by a poorer phenotype and prognosis.<sup><xref ref-type="bibr" rid="bibr48-1756286419845567">48</xref></sup> Nevertheless, some congenital patients show normal intellectual functioning
and brain structure.<sup><xref ref-type="bibr" rid="bibr15-1756286419845567">15</xref></sup> Cognitive impairment in the adult-onset form is more subtle. CNS involvement
has been highlighted in several studies.<sup><xref ref-type="bibr" rid="bibr49-1756286419845567">49</xref>,<xref ref-type="bibr" rid="bibr50-1756286419845567">50</xref></sup> Neurocognitive deficits mainly
affect memory, executive, verbal, and visuospatial functions. Behavioral changes,
apathy, change of personality, anosognosia, and daytime somnolence have been found
and are associated to a poorer quality of life.<sup><xref ref-type="bibr" rid="bibr41-1756286419845567">41</xref>,<xref ref-type="bibr" rid="bibr51-1756286419845567">51</xref><xref ref-type="bibr" rid="bibr52-1756286419845567"></xref>–<xref ref-type="bibr" rid="bibr53-1756286419845567">53</xref></sup> A cognitive progression over
time has been confirmed.<sup><xref ref-type="bibr" rid="bibr54-1756286419845567">54</xref><xref ref-type="bibr" rid="bibr55-1756286419845567"></xref><xref ref-type="bibr" rid="bibr56-1756286419845567"></xref>–<xref ref-type="bibr" rid="bibr57-1756286419845567">57</xref></sup> Brain changes have been
reported but, until now, the pathophysiology and temporal development of brain
involvement still remain unclear. Premature aging neurofibrillary tangles (NFTs) and
a related degenerative disorder process have been observed in different cerebral structures.<sup><xref ref-type="bibr" rid="bibr47-1756286419845567">47</xref></sup> Widespread neuronal loss (cortical and subcortical), increase in perivascular
Virchow–Robinson space, rarefaction in deep WM, mild gliosis, and capillary
hyalinization have been detected in postmortem studies.<sup><xref ref-type="bibr" rid="bibr58-1756286419845567">58</xref></sup> Nevertheless, it remains difficult to define a specific lesion pattern since
the resulting data are often difficult to replicate. Findings from the first CT
scans published in the 1980s, showed a morphological affection in patients with DM1
characterized by ventricular increased and cerebral atrophy.<sup><xref ref-type="bibr" rid="bibr59-1756286419845567">59</xref><xref ref-type="bibr" rid="bibr60-1756286419845567"></xref><xref ref-type="bibr" rid="bibr61-1756286419845567"></xref>–<xref ref-type="bibr" rid="bibr62-1756286419845567">62</xref></sup> Microcephaly, hyperostosis
internal frontalis, and thickening in the calvarium were detected by Avrahami and
colleagues and may be due to brain atrophy.<sup><xref ref-type="bibr" rid="bibr63-1756286419845567">63</xref></sup> A 0.5 T cranial investigation (1988) revealed perivascular hyperintensities
as well as a ventricular enlargement in patients compared with controls.<sup><xref ref-type="bibr" rid="bibr64-1756286419845567">64</xref></sup> Early neuroimaging investigations using a structural nonquantitative MRI
approach frequently reported WM hyperintense load (WMHL),<sup><xref ref-type="bibr" rid="bibr65-1756286419845567">65</xref><xref ref-type="bibr" rid="bibr66-1756286419845567"></xref>–<xref ref-type="bibr" rid="bibr67-1756286419845567">67</xref></sup> subcortical and
periventricular WM hyperintense lesions, cerebral atrophy, thickening or atrophy of
the corpus callosum, and dilated Virchow–Robin space.<sup><xref ref-type="bibr" rid="bibr48-1756286419845567">48</xref>,<xref ref-type="bibr" rid="bibr58-1756286419845567">58</xref>,<xref ref-type="bibr" rid="bibr68-1756286419845567">68</xref><xref ref-type="bibr" rid="bibr69-1756286419845567"></xref><xref ref-type="bibr" rid="bibr70-1756286419845567"></xref>–<xref ref-type="bibr" rid="bibr71-1756286419845567">71</xref></sup> In particular, WMHLs have been
detected using different scales, such as Fazekas or ARWMCs.<sup><xref ref-type="bibr" rid="bibr41-1756286419845567">41</xref>,<xref ref-type="bibr" rid="bibr67-1756286419845567">67</xref></sup> The prevalence
of WMLs in DM1 patients seems to be related to neuropsychological
deficits,<sup><xref ref-type="bibr" rid="bibr47-1756286419845567">47</xref>,<xref ref-type="bibr" rid="bibr65-1756286419845567">65</xref></sup> patients’ age, disease progression,<sup><xref ref-type="bibr" rid="bibr47-1756286419845567">47</xref>,<xref ref-type="bibr" rid="bibr72-1756286419845567">72</xref></sup> and CTG expansion size.<sup><xref ref-type="bibr" rid="bibr65-1756286419845567">65</xref></sup> The temporopolar WM pathology in DM1 seems to be the most robust and
reproducible finding characterizing patients with DM1 rather than DM2, although
clinical correlations and evolutions remain unclear (<xref ref-type="fig" rid="fig1-1756286419845567">Figure 1</xref>).<sup><xref ref-type="bibr" rid="bibr47-1756286419845567">47</xref>,<xref ref-type="bibr" rid="bibr65-1756286419845567">65</xref><xref ref-type="bibr" rid="bibr66-1756286419845567"></xref><xref ref-type="bibr" rid="bibr67-1756286419845567"></xref>–<xref ref-type="bibr" rid="bibr68-1756286419845567">68</xref>,<xref ref-type="bibr" rid="bibr71-1756286419845567">71</xref></sup> A long-term follow-up study
suggested that those abnormalities might be progressive over time. WMLs, when absent
at baseline, may appear during the course of the disease, proving the existence of a
slow demyelinating process in the adult form.<sup><xref ref-type="bibr" rid="bibr73-1756286419845567">73</xref></sup> Progression over time in the number and extent of WMLs and brain atrophy
suggests that WM involvement in the adult form is degenerative.<sup><xref ref-type="bibr" rid="bibr73-1756286419845567">73</xref></sup> However, other authors have not found this potential correlation between
progression and age,<sup><xref ref-type="bibr" rid="bibr48-1756286419845567">48</xref>,<xref ref-type="bibr" rid="bibr51-1756286419845567">51</xref>,<xref ref-type="bibr" rid="bibr71-1756286419845567">71</xref>,<xref ref-type="bibr" rid="bibr74-1756286419845567">74</xref><xref ref-type="bibr" rid="bibr75-1756286419845567"></xref>–<xref ref-type="bibr" rid="bibr76-1756286419845567">76</xref></sup> or
neuropsychological testing and the degree of neuromuscular involvement.<sup><xref ref-type="bibr" rid="bibr77-1756286419845567">77</xref></sup></p>
<fig id="fig1-1756286419845567" orientation="portrait" position="float">
<label>Figure 1.</label>
<caption>
<p>47-year-old male affected by myotonic dystrophy type 1 (with a sister
affected by the same pathology) with moderate cognitive involvement, (MIRS)
= 3, first symptoms onset at age 26 years, CTG = 413, expansion class =
E2.</p>
<p>(a) Marked white matter change abnormality around frontal horn detected in a
FLAIR brain MRI scan (red arrow). Left ventricle appears larger than
right.</p>
<p>(b) In the temporopolar area at the level of insula marked changes of white
matter with major involvement on the left side (red arrow). In brain stem,
there is marked atrophy of quadrigeminal bodies and atrophy of pons on the
left side (green box). The third ventricle is dilated.</p>
<p>CTG, Cytosine-Thymine-Guanine; FLAIR, fluid-attenuated inversion recovery;
MIRS, muscular impairment rating scale; MRI, magnetic resonance imaging.</p>
</caption>
<graphic xlink:href="10.1177_1756286419845567-fig1"></graphic>
</fig>
<fig id="fig2-1756286419845567" orientation="portrait" position="float">
<label>Figure 2.</label>
<caption>
<p>Brain MRI of a patient with CMD.</p>
<p>Axial T2 images show evidence of severe white matter abnormalities,
pachygyria in the occipital lobes and ventricular enlargement.</p>
<p>CMD, congenital muscular dystrophy; MRI, magnetic resonance imaging.</p>
</caption>
<graphic xlink:href="10.1177_1756286419845567-fig2"></graphic>
</fig>
<p>Brain atrophy and GM volume reduction in cortical lobes and in deep structures have
frequently been reported in literature. It is noted to be mostly symmetric and more
pronounced in adult onset but no agreement has been found on the congenital,
juvenile, and adult onset form. A recent review published in 2017 revealed a general
volume reduction in all cortical lobes, the basal ganglia, and cerebrum.<sup><xref ref-type="bibr" rid="bibr78-1756286419845567">78</xref></sup> The development of observer-independent techniques enabled the estimation of
systemic brain atrophy and the relationship with clinical parameters. Comparing GM
and WM volumes in noncongenital DM1 patients, Antonini and colleagues found
widespread global volume reductions in patients and a negative correlation between
age and GM volume.<sup><xref ref-type="bibr" rid="bibr79-1756286419845567">79</xref></sup> No correlation was found between age and WM volume. In light of this, they
postulated the existence of a neurodevelopmental GM loss process progressive with
age independent from the WMHL degeneration process.<sup><xref ref-type="bibr" rid="bibr79-1756286419845567">79</xref></sup> In contrast, Weber described a correlation between disease duration and WMHL.<sup><xref ref-type="bibr" rid="bibr52-1756286419845567">52</xref></sup> Recently, Baldanzi and colleagues estimated brain atrophy using BPF and found
a correlation between atrophy and visuospatial and frontal tasks.<sup><xref ref-type="bibr" rid="bibr41-1756286419845567">41</xref></sup></p>
<p>Several volumetric analysis based on automated methods (e.g. VBM) described
widespread GM volume loss both in cortical areas (frontal, temporal, parietal and
occipital cortices) and subcortical structures (such as thalami, putamen, and
caudate nucleus) and cerebellum with a significant involvement of the corpus
callosum (anterior, medioanterior, central, mediodorsal regions) in noncongenital
patients.<sup><xref ref-type="bibr" rid="bibr41-1756286419845567">41</xref>,<xref ref-type="bibr" rid="bibr47-1756286419845567">47</xref>,<xref ref-type="bibr" rid="bibr48-1756286419845567">48</xref>,<xref ref-type="bibr" rid="bibr52-1756286419845567">52</xref>,<xref ref-type="bibr" rid="bibr72-1756286419845567">72</xref>,<xref ref-type="bibr" rid="bibr79-1756286419845567">79</xref><xref ref-type="bibr" rid="bibr80-1756286419845567"></xref>–<xref ref-type="bibr" rid="bibr81-1756286419845567">81</xref></sup> Occipital
involvement has been detected only in a few cases, which correlates with
visuospatial impairment.<sup><xref ref-type="bibr" rid="bibr48-1756286419845567">48</xref></sup></p>
<p>Correlation between sleeplessness and volume loss in the right pallidum and
diencephalon has been found.<sup><xref ref-type="bibr" rid="bibr48-1756286419845567">48</xref></sup></p>
<p>Variable reduction of temporal volume has been documented: while described the volume
preservation of temporal lobe only few authors have reported volume reduction in the
hippocampus.<sup><xref ref-type="bibr" rid="bibr47-1756286419845567">47</xref>,<xref ref-type="bibr" rid="bibr52-1756286419845567">52</xref>,<xref ref-type="bibr" rid="bibr67-1756286419845567">67</xref>,<xref ref-type="bibr" rid="bibr72-1756286419845567">72</xref>,<xref ref-type="bibr" rid="bibr82-1756286419845567">82</xref></sup></p>
<p>In patients with different disease onset, GM volume reduction has only been detected
in adult onset (not in the congenital form) and an increased volume loss in the
cortex is associated with age.<sup><xref ref-type="bibr" rid="bibr48-1756286419845567">48</xref>,<xref ref-type="bibr" rid="bibr83-1756286419845567">83</xref>,<xref ref-type="bibr" rid="bibr84-1756286419845567">84</xref></sup> Unchanged subcortical GM
volume has been found, excluding patients with congenital/childhood onset.<sup><xref ref-type="bibr" rid="bibr72-1756286419845567">72</xref></sup> Correlations between CTG repeat length and GM volumes in motor-related
structure and frontal areas, and between pontine WM changes and depression score
have been reported.<sup><xref ref-type="bibr" rid="bibr80-1756286419845567">80</xref>,<xref ref-type="bibr" rid="bibr81-1756286419845567">81</xref>,<xref ref-type="bibr" rid="bibr85-1756286419845567">85</xref></sup></p>
<p>In general, neuroimaging parameters do not correlate with cognitive performance and
only an association between delayed recall of verbal memory test and the volume of
left postcentral, left middle, and inferior temporal gyri and left supramarginal
gyrus has been found.<sup><xref ref-type="bibr" rid="bibr41-1756286419845567">41</xref></sup></p>
<p>Fewer WM changes using a VBM technique have been found. Noncongenital patients showed
a diffuse WM volume reduction in every lobe and in the corpus callosum.<sup><xref ref-type="bibr" rid="bibr48-1756286419845567">48</xref>,<xref ref-type="bibr" rid="bibr67-1756286419845567">67</xref>,<xref ref-type="bibr" rid="bibr80-1756286419845567">80</xref>,<xref ref-type="bibr" rid="bibr81-1756286419845567">81</xref></sup></p>
<p>To our knowledge, only two studies have been carried out on cortical thickness.
Zanigni and colleagues observed a lateral-occipital thinning in the bilateral
cortex, in the right precentral and in the left superior-parietal, fusiform and
superior-temporal cortex.<sup><xref ref-type="bibr" rid="bibr72-1756286419845567">72</xref></sup> A more diffused thickness reduction in the frontal, temporal, and occipital
cortex has been observed instead.<sup><xref ref-type="bibr" rid="bibr86-1756286419845567">86</xref></sup></p>
<p>The first DTI study was performed by Ota and colleagues and revealed diffusivity
abnormalities in the corpus callosum in noncongenital patients with DM1 associated
with GM volume reduction.<sup><xref ref-type="bibr" rid="bibr80-1756286419845567">80</xref></sup> Other studies have recently demonstrated diffuse microstructural WM damage
with widespread functional anisotropy reduction and increased mean diffusivity in
fibers (i.e. corpus callosum, corticospinal tracts)<sup><xref ref-type="bibr" rid="bibr41-1756286419845567">41</xref>,<xref ref-type="bibr" rid="bibr47-1756286419845567">47</xref>,<xref ref-type="bibr" rid="bibr48-1756286419845567">48</xref>,<xref ref-type="bibr" rid="bibr72-1756286419845567">72</xref>,<xref ref-type="bibr" rid="bibr85-1756286419845567">85</xref>,<xref ref-type="bibr" rid="bibr86-1756286419845567">86</xref></sup> even for child and adolescent
onset.<sup><xref ref-type="bibr" rid="bibr84-1756286419845567">84</xref>,<xref ref-type="bibr" rid="bibr87-1756286419845567">87</xref>,<xref ref-type="bibr" rid="bibr88-1756286419845567">88</xref></sup> In particular, an association between diffusivity values and IQ
score was found and between FA and muscular dystrophy values in frontal and temporal
lobes and working memory performance.<sup><xref ref-type="bibr" rid="bibr87-1756286419845567">87</xref>,<xref ref-type="bibr" rid="bibr88-1756286419845567">88</xref></sup> In noncongenital patients
correlations between diffusivity parameters and MMSE,<sup><xref ref-type="bibr" rid="bibr72-1756286419845567">72</xref>,<xref ref-type="bibr" rid="bibr85-1756286419845567">85</xref></sup> visuospatial impairment,<sup><xref ref-type="bibr" rid="bibr48-1756286419845567">48</xref></sup> visuomotor coordination and working memory tasks<sup><xref ref-type="bibr" rid="bibr41-1756286419845567">41</xref></sup> or attentional scores<sup><xref ref-type="bibr" rid="bibr47-1756286419845567">47</xref></sup> were detected. CTG repeat length association was found with DTI
parameters<sup><xref ref-type="bibr" rid="bibr67-1756286419845567">67</xref>,<xref ref-type="bibr" rid="bibr88-1756286419845567">88</xref></sup> even diffused for the entire brain.<sup><xref ref-type="bibr" rid="bibr85-1756286419845567">85</xref>,<xref ref-type="bibr" rid="bibr89-1756286419845567">89</xref></sup> Correlations between DTI
values and the muscular impairment rating scale (MIRS) score<sup><xref ref-type="bibr" rid="bibr67-1756286419845567">67</xref>,<xref ref-type="bibr" rid="bibr85-1756286419845567">85</xref>,<xref ref-type="bibr" rid="bibr90-1756286419845567">90</xref></sup> were evidenced
and only one study reported correlation with disease duration or age.<sup><xref ref-type="bibr" rid="bibr67-1756286419845567">67</xref></sup> Sleepiness or fatigue were investigated in four studies, but only two found
significant correlations.<sup><xref ref-type="bibr" rid="bibr67-1756286419845567">67</xref>,<xref ref-type="bibr" rid="bibr90-1756286419845567">90</xref></sup> Some authors, detecting abnormalities in the corpus callosum,
suggested that the microstructural abnormalities might be the result of Wallerian
degeneration following GM atrophy.<sup><xref ref-type="bibr" rid="bibr80-1756286419845567">80</xref>,<xref ref-type="bibr" rid="bibr84-1756286419845567">84</xref></sup> On the other hand, other
authors underlined the predominance of WM degeneration and its diffusion when
compared with GM effects in DM1.<sup><xref ref-type="bibr" rid="bibr67-1756286419845567">67</xref></sup> Caso and colleagues detected the existence of WM abnormalities in the
juvenile form that could lead to GM degeneration. They concluded that
microstructural WM change might be due to development change in congenital or
child-onset forms while GM degeneration may be more related to a degenerative
process considering the aging (premature aging).<sup><xref ref-type="bibr" rid="bibr47-1756286419845567">47</xref></sup> The independence of WM and GM neurodegenerative processes is suggested by the
presence of WM T2 hyperintense lesions, whereas there is no correlation with GM
loss. This supports the existence of two independent degenerative processes
involving WM and cortical degeneration.<sup><xref ref-type="bibr" rid="bibr79-1756286419845567">79</xref></sup></p>
<p>Recently, fMRI studies conducted during a motor task, reported an altered activation
in sensory-motor network, including motor control areas, inferior parietal lobes,
basal ganglia, and thalami, in patients with DM1 with myotonia compared with
controls. The authors hypothesized that a greater motor area activation reflected a
compensatory mechanism involved in an accelerated aging process.<sup><xref ref-type="bibr" rid="bibr91-1756286419845567">91</xref></sup> Toth and colleagues investigated the impact of myotonia during a grip task
and they found no correlations between clinical characteristic in motor performance
and neurofunctional findings, assuming independence between brain functioning and
myotonia development.<sup><xref ref-type="bibr" rid="bibr92-1756286419845567">92</xref></sup> Connectivity between brain regions estimated with an rs-fMRI examination
revealed an abnormal functional connectivity in the default model network associated
with schizotypal-paranoid traits.<sup><xref ref-type="bibr" rid="bibr89-1756286419845567">89</xref></sup></p>
<p>Later, the same research group, investigating social cognition abilities through
theory of mind, found a correlation between difficulties in social interactions and
personality with connectivity abnormalities.<sup><xref ref-type="bibr" rid="bibr93-1756286419845567">93</xref></sup> Moreover, the dysfunctional network seemed to be correlated with impairment
in visuospatial abilities.<sup><xref ref-type="bibr" rid="bibr93-1756286419845567">93</xref></sup> The authors argued that in DM1 patients the decreased frontoparietal
connectivity might be linked to cognitive and behavioral disorders and changes in
connectivity might represent a compensatory or maladaptive process related to the
disease.</p>
<p>Park and colleagues studied functional alterations in the resting state sensorimotor
network analyzing the power spectral density (PSD) and noted a widespread PSD
alteration in GM and WM. In particular, GM reduction and increased functionality
were found in brain regions involved in visual processing, which were associated
with motor performance. A subtle increased functional difference was detected in WM
associated with motor function. These findings suggest that motor disability in DM1
is not an isolated deterioration of structures involved in motor coordination and
regulation but also a multimodal dysfunction that includes the visual system.<sup><xref ref-type="bibr" rid="bibr94-1756286419845567">94</xref></sup></p>
<p>Fiorelli and colleagues conducted the first FDG-PET research in DM1 and found a
reduced glucose metabolism in patients compared with healthy controls.<sup><xref ref-type="bibr" rid="bibr95-1756286419845567">95</xref></sup> Later, widespread rising in glucose uptake in the cortical and subcortical
structure was found.<sup><xref ref-type="bibr" rid="bibr96-1756286419845567">96</xref></sup> Frontal and temporal lobes are mainly involved.<sup><xref ref-type="bibr" rid="bibr52-1756286419845567">52</xref>,<xref ref-type="bibr" rid="bibr95-1756286419845567">95</xref>,<xref ref-type="bibr" rid="bibr97-1756286419845567">97</xref>,<xref ref-type="bibr" rid="bibr98-1756286419845567">98</xref></sup> Renard and colleagues reported
a frontal bilateral reduction in FDG uptake, while no differences were observed in
deep GM structures.<sup><xref ref-type="bibr" rid="bibr99-1756286419845567">99</xref></sup></p>
<p>In a recent study Peric and colleagues, excluding congenital and late-onset patients,
detected hypometabolism in frontotemporal regions and a correlation between right
frontotemporal glucose uptake and executive function.<sup><xref ref-type="bibr" rid="bibr100-1756286419845567">100</xref></sup> SPECT investigation revealed that CBF and perfusion were reduced in DM1,
mainly in the frontotemporal region.<sup><xref ref-type="bibr" rid="bibr101-1756286419845567">101</xref></sup> Hypoperfusion, more pronounced in the left hemisphere, was found in frontal
and parieto-occipital regions in a large DM1 sample, and this also correlated with
the MIRS score.<sup><xref ref-type="bibr" rid="bibr98-1756286419845567">98</xref></sup></p>
<p>Frontal rCBF reduction (frontal mesial and dorsolateral frontal cortex),
hypoperfusion in the posterior cortical regions) and in the right parietal lobe
correlates with deficits in visuospatial and memory function.<sup><xref ref-type="bibr" rid="bibr102-1756286419845567">102</xref></sup> These results are in agreement with a previous H<sub>2</sub>O-PET
investigation in which authors described a reduction of CBF in the frontotemporal
cortex, hypothalamus, and left basal ganglia,<sup><xref ref-type="bibr" rid="bibr77-1756286419845567">77</xref></sup> which was also reported in two other childhood-onset patients.<sup><xref ref-type="bibr" rid="bibr103-1756286419845567">103</xref></sup></p>
<p>Transcranial B-mode sonography is a noninvasive technique used to assess brain
structure and integrity, ventricular enlargement, or hydrocephalus. Transcranial
ultrasound B-mode examinations have been proved useful to measure ventricular
enlargement in adult-onset DM1, as well as to detect changes in the echogenicity of
specific brainstem structures. Both studies revealed a brainstem raphe
hypoechogenicity and hyperechogenicity of the substantia nigra and by increased
width of the third ventricle in patients with DM1.<sup><xref ref-type="bibr" rid="bibr104-1756286419845567">104</xref>,<xref ref-type="bibr" rid="bibr105-1756286419845567">105</xref></sup> All these findings
contribute to understanding the pathophysiology process of cerebral involvement in
DM1. Nevertheless, the conflicting results found in these studies can be explained
by the high clinical variability of DM1 and the different age of onset.</p>
<sec id="section7-1756286419845567">
<title>Myotonic dystrophy type 2</title>
<p>DM2 shares the RNA pathogenesis with type 1 but fewer studies focusing on DM2 are
available. The symptom onset typically occurs in the third decade. Developmental
abnormalities and severe childhood disorders are not associated.<sup><xref ref-type="bibr" rid="bibr106-1756286419845567">106</xref></sup> DM2 clinically differs from DM1 in the degree of cognitive impairment.
While DM1 congenital forms can exhibit severe mental retardation, this has not
been reported in DM2. The first description of brain involvement in patients
with DM2, characterized by diffuse and confluent WM hyperintense lesions, was
provided by Hund and colleagues, while the early findings of global atrophy were
reported by Kassubek and colleagues.<sup><xref ref-type="bibr" rid="bibr107-1756286419845567">107</xref>,<xref ref-type="bibr" rid="bibr108-1756286419845567">108</xref></sup> Using a conventional MRI
approach diffuse WMHLs have been detected mainly in periventricular space and
frontoparieto-occipital structures.<sup><xref ref-type="bibr" rid="bibr52-1756286419845567">52</xref>,<xref ref-type="bibr" rid="bibr65-1756286419845567">65</xref>,<xref ref-type="bibr" rid="bibr66-1756286419845567">66</xref>,<xref ref-type="bibr" rid="bibr77-1756286419845567">77</xref></sup> without any association
with cognitive performance.<sup><xref ref-type="bibr" rid="bibr65-1756286419845567">65</xref>,<xref ref-type="bibr" rid="bibr77-1756286419845567">77</xref></sup> Some of them demonstrated
patterns of hyperintense lesions in DM2 similar to those noted in DM1.<sup><xref ref-type="bibr" rid="bibr66-1756286419845567">66</xref>,<xref ref-type="bibr" rid="bibr77-1756286419845567">77</xref></sup> Kornblum
and colleagues described atrophy in patients with DM2 using a 1.5 T scanner.
They found no significant correlation between BPF and clinical features.<sup><xref ref-type="bibr" rid="bibr66-1756286419845567">66</xref></sup> Later, other studies reported brain atrophy in patients with
DM2.<sup><xref ref-type="bibr" rid="bibr52-1756286419845567">52</xref>,<xref ref-type="bibr" rid="bibr67-1756286419845567">67</xref>,<xref ref-type="bibr" rid="bibr81-1756286419845567">81</xref>,<xref ref-type="bibr" rid="bibr109-1756286419845567">109</xref></sup> GM and WM loss along brain midline structures have
been identified in patients with DM2.<sup><xref ref-type="bibr" rid="bibr52-1756286419845567">52</xref>,<xref ref-type="bibr" rid="bibr67-1756286419845567">67</xref>,<xref ref-type="bibr" rid="bibr81-1756286419845567">81</xref></sup> Some VBM analysis found
cortical and subcortical (thalamus, hypothalamus, and brainstem) GM reduction
but these findings were never replicated. Only diffuse changes in WM and the
corpus callosum have been replicated.<sup><xref ref-type="bibr" rid="bibr109-1756286419845567">109</xref></sup> Schenierd-Gold and colleagues observed a GM loss in the cuneus, temporal
regions, and amygdala and a prominent WM frontal atrophy without strong
correlation between neuroimaging findings and cognitive features.<sup><xref ref-type="bibr" rid="bibr81-1756286419845567">81</xref>,<xref ref-type="bibr" rid="bibr110-1756286419845567">110</xref></sup>
Interestingly, they found that reductions in mediofrontal GM and cerebellar
peduncles and pars of pons WM was associated with excessive day time sleepiness,
while brain strain atrophy was correlated with depression.<sup><xref ref-type="bibr" rid="bibr81-1756286419845567">81</xref></sup> A correlation between hippocampal volume and episodic memory was
found.<sup><xref ref-type="bibr" rid="bibr52-1756286419845567">52</xref>,<xref ref-type="bibr" rid="bibr67-1756286419845567">67</xref></sup></p>
<p>WM alterations in patients with DM2 were carefully detected by DTI techniques and
associated with different results. The corpus callosum, internal and external
capsules, and limbic system are microstructurally impaired in patients with DM2
compared with controls, nevertheless less than DM1.<sup><xref ref-type="bibr" rid="bibr67-1756286419845567">67</xref></sup> The correlation between abnormal WM and clinical features appears
controversial. Found an association between age, disease duration, depression,
and motor performance and DTI parameters. No significant correlations were found
later between neuropsychological performance and the brain microstructure.<sup><xref ref-type="bibr" rid="bibr67-1756286419845567">67</xref></sup> This discrepancy might be due to small and different sample sizes. No
difference in a DTI-ROI-based study was found in FA parameters comparing
patients with DM2 with controls.<sup><xref ref-type="bibr" rid="bibr84-1756286419845567">84</xref></sup></p>
<p>The first functional imaging study demonstrated a reduced regional CBF in the
orbital and medial frontal structures detected with H<sub>2</sub>O<sup><xref ref-type="bibr" rid="bibr15-1756286419845567">15</xref></sup>-PET in patients with DM2.<sup><xref ref-type="bibr" rid="bibr77-1756286419845567">77</xref></sup> These anatomic changes appear to have some effect on cognition, behavior,
and personality, although unlike DM1, DM2 has not been associated with
intellectual disability.<sup><xref ref-type="bibr" rid="bibr102-1756286419845567">102</xref></sup></p>
<p>An FDG-PET study found significant widespread hypometabolism of glucose in
frontal and temporal lobes and, comparing patterns of GM volumes and
hypometabolism (FDG-PET), Weber and collegues colncluded that hypometabolism was
an independent phenomenon not resulting from the GM atrophy process.<sup><xref ref-type="bibr" rid="bibr52-1756286419845567">52</xref></sup> Moreover, as previously mentioned, no correlation between functional
parameters and neuropsychological features were found.<sup><xref ref-type="bibr" rid="bibr52-1756286419845567">52</xref></sup> On the contrary, Peric and colleagues observed numerous correlations
between hypometabolism in prefrontal, insular, and striatal structures and
attentive deficit and association between executive dysfunction and
frontotemporal hypometabolism.<sup><xref ref-type="bibr" rid="bibr57-1756286419845567">57</xref></sup></p>
<p>According to results obtained in PET studies, Meola and colleagues detected
hypometabolism in frontal, parieto-occipital brain regions using SPECT,<sup><xref ref-type="bibr" rid="bibr102-1756286419845567">102</xref></sup> while Romeo found the most significant hypoperfusion in the (left)
parietal area.<sup><xref ref-type="bibr" rid="bibr65-1756286419845567">65</xref></sup></p>
<p>Only two studies using TCS have been published.<sup><xref ref-type="bibr" rid="bibr105-1756286419845567">105</xref>,<xref ref-type="bibr" rid="bibr111-1756286419845567">111</xref></sup> Significant enlargement
of the third ventricle in patients with DM2 compared with controls was found. A
correlation between the pathological raphe signal and excessive daytime
sleepiness (EDS) was detected.<sup><xref ref-type="bibr" rid="bibr105-1756286419845567">105</xref></sup> Rakocevic-Stojanovic and colleagues observed a higher frequency of
brainstem raphe and substantia nigra hypoechogenicity. The diameter of the third
ventricle resulted increased and was associated with depression and EDS.
Brainstem raphe hypoechogenicity was associated with EDS and diameter of the
third ventricle with depression. EDS and fatigue were correlated to brainstem
values. No correlation with the substantia nigra with depression or fatigue were found.<sup><xref ref-type="bibr" rid="bibr111-1756286419845567">111</xref></sup> All the above-described neuroimaging evidence suggests a brain
involvement in DM2 strengthened by clinical data milder than DM1.</p>
</sec>
<sec id="section8-1756286419845567">
<title>The dystrophinopathies: Duchenne and Becker muscular dystrophies</title>
<p>DMD and BMD are X-linked neuromuscular disorders characterized by a progressive
muscular impairment due to a lack of dystrophin. Dystrophin is fundamental for
the structural integrity of muscle membranes. DMD is characterized by
absent/nonfunctional muscle dystrophin protein. In BMD, dystrophin might be
short in size. Progressive weakness of the legs, pelvic and shoulder muscles and
heart failure start in early childhood and weakness is generally more severe in
patients with DMD than BMD. Striated muscle and heart involvement are mostly
described in the literature in patients with DMD. Cardiomyopathy may be the
first disease manifestation without evident skeletal myopathy in BMD.<sup><xref ref-type="bibr" rid="bibr112-1756286419845567">112</xref></sup> Striated muscle and heart involvement are deeply described in the
literature, in particular in patients with DMD. Male patients with DMD may
develop early respiratory muscle failure causing death in the third decades
generally due to cardiac and pulmonary complications.<sup><xref ref-type="bibr" rid="bibr113-1756286419845567">113</xref></sup> The occurrence of neurocognitive deficits in DMD are well described and
seem to be related to the reduced level of dystrophin isoforms and its location
in CNS tissues.<sup><xref ref-type="bibr" rid="bibr114-1756286419845567">114</xref><xref ref-type="bibr" rid="bibr115-1756286419845567"></xref><xref ref-type="bibr" rid="bibr116-1756286419845567"></xref>–<xref ref-type="bibr" rid="bibr117-1756286419845567">117</xref></sup> Nevertheless, the role
of dystrophin in the brain is not well established. Mutations within the
<italic>DMD</italic> gene result in the absence of specific dystrophin
isoforms. The location of dystrophin isoforms has been linked with cognitive
impairment in DMD. The lack of dystrophin in the brain is localized in neurons
and glial cells in the hippocampal, cortical, and subcortical regions, and
Purkinje cells of the cerebellum.<sup><xref ref-type="bibr" rid="bibr118-1756286419845567">118</xref></sup> Information on dystrophin in the brain is based on few studies on human
brains.<sup><xref ref-type="bibr" rid="bibr119-1756286419845567">119</xref>,<xref ref-type="bibr" rid="bibr120-1756286419845567">120</xref></sup> Isoform Dp427c is predominantly expressed in the
neurons of the cortex and hippocampus.<sup><xref ref-type="bibr" rid="bibr121-1756286419845567">121</xref></sup> The Purkinje isoform Dp427p is expressed in cerebellar Purkinje cells,
Dp260 and Dp116 isoforms in the retina and the peripheral nerve, Dp71 isoform
presents higher levels in the CNS.<sup><xref ref-type="bibr" rid="bibr122-1756286419845567">122</xref>,<xref ref-type="bibr" rid="bibr123-1756286419845567">123</xref></sup> Less informtions are
available on Dp140.<sup><xref ref-type="bibr" rid="bibr124-1756286419845567">124</xref></sup> Recently DMD expression level in the adult human brain has been found to
be higher in the hippocampus, involved in memory and amygdala as well as emotion
regulation, rather than in the cerebellum and the pons. The high expression of
DMD in subcortical structures might support evidence of memory and emotion
deficits in DMD.<sup><xref ref-type="bibr" rid="bibr120-1756286419845567">120</xref></sup> Duchenne himself, described some patients with cognitive deficits.<sup><xref ref-type="bibr" rid="bibr125-1756286419845567">125</xref></sup></p>
<p>It has been estimated that 30% of boys with DMD present cognitive deficits and
mental retardation. Children with DMD show lower IQ scores than the normal
population (average IQ score in patients with DMD is 85) and this average is one
standard deviation below the mean (30% of boys with DMD have an IQ &gt; 70).<sup><xref ref-type="bibr" rid="bibr126-1756286419845567">126</xref></sup> Worse performance in attentional and verbal repetition tasks has been
described.<sup><xref ref-type="bibr" rid="bibr127-1756286419845567">127</xref><xref ref-type="bibr" rid="bibr128-1756286419845567"></xref>–<xref ref-type="bibr" rid="bibr129-1756286419845567">129</xref></sup> Reading
deficits, attention-deficit hyperactivity disorder, autism spectrum disorders,
epilepsy, and obsessive–compulsive disorder (OCD) have also been
observed.<sup><xref ref-type="bibr" rid="bibr130-1756286419845567">130</xref><xref ref-type="bibr" rid="bibr131-1756286419845567"></xref><xref ref-type="bibr" rid="bibr132-1756286419845567"></xref><xref ref-type="bibr" rid="bibr133-1756286419845567"></xref>–<xref ref-type="bibr" rid="bibr134-1756286419845567">134</xref></sup> Spelling, arithmetic,
reading difficulties behavioral problems<sup><xref ref-type="bibr" rid="bibr115-1756286419845567">115</xref></sup> and the occurrence of epilepsy<sup><xref ref-type="bibr" rid="bibr135-1756286419845567">135</xref></sup> have been described in BMD but neurodevelopmental disorders have been
investigated less than in DMD. Regarding DMD brain imaging, Septien and
colleagues used CT scans in 15 patients with DMD. The authors detected cortical
atrophy associated with minimal ventricular dilatation probably due to WM abnormalities.<sup><xref ref-type="bibr" rid="bibr136-1756286419845567">136</xref></sup> A decade before Yoshioka and colleagues investigated 30 patients with DMD
with the same techniques found subtle cortical atrophy in 67% of them, which was
associated with slight ventricular dilation.<sup><xref ref-type="bibr" rid="bibr137-1756286419845567">137</xref></sup> Enlargement of the lateral ventricles of the brain in mdx mice, when
compared with controls, has been detected recently.<sup><xref ref-type="bibr" rid="bibr138-1756286419845567">138</xref></sup> Brain MRI evaluation showed that patients with DMD lacking Dp140 isoforms
performed worse on neuropsychological evaluation compared with those with
preserved Dp140. They found some difference on a structural level where patients
showed significantly smaller occipital cortex volumes and a difference in FA
parameters in the occipital lobe.<sup><xref ref-type="bibr" rid="bibr139-1756286419845567">139</xref></sup> The authors concluded that the DMD_Dp140(-) mutation may contribute more
to GM volume reduction. There was no statistical difference in WM volume. A kind
of alteration in WM microstructural integrity (lower WM FA, higher WM mean and
radial diffusivity), indicating compromised structural complexity, comparing
patients with DMD with healthy controls has been found.<sup><xref ref-type="bibr" rid="bibr139-1756286419845567">139</xref></sup> Using DTI-ROI-based approaches and selecting 16 different structures
bilaterally, Fu and colleagues found changes in the corpus callosum and, in
particular, in the splenium.<sup><xref ref-type="bibr" rid="bibr113-1756286419845567">113</xref></sup> However, both the small size of ROI used and the lack of multiple
correction comparisons are the limits of the study. Lv and colleagues, assessing
motor-related brain cortex, found the smaller volume in the left primary
sensorimotor cortex in DMD.<sup><xref ref-type="bibr" rid="bibr140-1756286419845567">140</xref></sup> The results on global morphological and microstructural differences in
the brain of patients with DMD suggest that these differences arise from altered
brain maturation rather than atrophy. Hypometabolism of glucose in boys affected
by DMD has been reported in the brain.<sup><xref ref-type="bibr" rid="bibr141-1756286419845567">141</xref></sup> Functional imaging technique showed a reduction of glucose metabolism
bilaterally in medial temporal structures and cerebellum and on the right side
in sensorimotor and lateral temporal cortex with PET<sup><xref ref-type="bibr" rid="bibr142-1756286419845567">142</xref></sup> and altered metabolite concentrations in the left cerebrum detected by SPECT.<sup><xref ref-type="bibr" rid="bibr143-1756286419845567">143</xref></sup> Using an rs-fMRI paradigm, a decrease of synchronization of spontaneous
activity in the motor cortex has been noted,<sup><xref ref-type="bibr" rid="bibr140-1756286419845567">140</xref></sup> underlying the existence of functional abnormalities in boys affected by
DMD which might be due to the deficiency of dystrophin in the brain.
Unfortunately, less information on brain imaging is available on BMD. This is
probably due to a milder phenotype characterizing the disorder that has led
researchers to focus on the more severe form of DMDs. Nevertheless, despite
various DMDs studies, etiology of the CNS pathology in DMD and BMD remains
unclear.</p>
</sec>
</sec>
<sec id="section9-1756286419845567">
<title>Glycogenosis disease type II</title>
<p>Glycogenosis type II (GSD II), also named Pompe disease, is an autosomal recessive
metabolic disorder caused by an accumulation of glycogen. Dysfunctional glycogen
storage is due to a deficiency of lysosomal enzyme α-glucosidase.<sup><xref ref-type="bibr" rid="bibr144-1756286419845567">144</xref></sup></p>
<p>Disease onset may occur in childhood or adulthood and infantile or late-onset forms
of classification have been proposed.<sup><xref ref-type="bibr" rid="bibr145-1756286419845567">145</xref></sup></p>
<p>The late-onset GSD II form mainly affects limb and respiratory muscles and is more
slowly progressive than the infantile-onset form.<sup><xref ref-type="bibr" rid="bibr146-1756286419845567">146</xref></sup></p>
<p>Postmortem evidence of glycogen accumulation in the brain of patients with GSD II has
been found,<sup><xref ref-type="bibr" rid="bibr147-1756286419845567">147</xref>,<xref ref-type="bibr" rid="bibr148-1756286419845567">148</xref></sup> without evidence of cortical atrophy.<sup><xref ref-type="bibr" rid="bibr149-1756286419845567">149</xref></sup></p>
<p>Infantile-onset Pompe Disease (IOPD) is a characterized by the accumulation of
glycogen in skeletal muscle, heart, and central neuronal tissue (cervical spinal
cord and the brainstem neurons with minimal build up in the cerebral
cortex)<sup><xref ref-type="bibr" rid="bibr150-1756286419845567">150</xref>,<xref ref-type="bibr" rid="bibr151-1756286419845567">151</xref></sup> even prenatally.<sup><xref ref-type="bibr" rid="bibr152-1756286419845567">152</xref></sup> Clinically characterized by general muscular weakness and respiratory and
cardiac dysfunctions, the symptomatology appears at the age of 6 months and results
in death before 1 year of age. Recombinant human α-glucosidase therapy has been
introduced since 1999 and has demonstrated an improvement in survival and a
reduction of symptoms.</p>
<p>Brain in IOPD disease is characterized by a delayed myelination, cortical atrophy and
a widening of the anterior horns of the lateral ventricles.<sup><xref ref-type="bibr" rid="bibr153-1756286419845567">153</xref></sup> Postmortem autopsies revealed glial cell accumulation in the WM in
IOPD.<sup><xref ref-type="bibr" rid="bibr150-1756286419845567">150</xref>,<xref ref-type="bibr" rid="bibr151-1756286419845567">151</xref></sup></p>
<p>Chien and colleagues described abnormal cranial findings (e.g. dilatation of the
lateral ventricles) associated with a delay of CNS myelination, evaluated with
repeated cranial MRI after 6 months of Enzyme Replacement Therapy (ERT).<sup><xref ref-type="bibr" rid="bibr154-1756286419845567">154</xref></sup> A slowly progressive neurodegenerative process affecting the motor neurons
has been detected in patients with infantile Pompe disease with MRI.<sup><xref ref-type="bibr" rid="bibr155-1756286419845567">155</xref></sup></p>
<p>Moreover, intellectual decline and extensive periventricular subcortical WMLs are
associated.<sup><xref ref-type="bibr" rid="bibr156-1756286419845567">156</xref>,<xref ref-type="bibr" rid="bibr157-1756286419845567">157</xref></sup> Progressive WM changes in early IOPD childhood have been
detected by Bloomfield and colleagues.<sup><xref ref-type="bibr" rid="bibr158-1756286419845567">158</xref></sup></p>
<p>Brain computed tomography (CT) and MRI of one patient case report performed over a
6-year follow up (at 3 and 9 years old) showed progressive global volume loss.<sup><xref ref-type="bibr" rid="bibr159-1756286419845567">159</xref></sup> While ventricle dilatation is a common feature in IOPD, myelination of the
cerebral WM has not been detected in T2-weighted images. Interestingly, the effect
of glycogen storage in the brain has been studied recently by Ebbink and colleagues
in a follow-up study of 11 patients.<sup><xref ref-type="bibr" rid="bibr157-1756286419845567">157</xref></sup> At a brain imaging point, they noted three characteristic stages of WM
involvement. The first phase is characterized by periventricular WM pattern at the
level of centrum semiovale associated to the widening of lateral ventricles. Growing
patients show WM abnormalities spreading to subcortical areas, the internal and
external capsule, first in the splenium and later in the genu of the corpus
callosum. At 11 years of age, hyperintensities were noted in decussation and
corticospinal tracts. This introduces new knowledge about the separate involvement
of the brain and motor functioning in Pompe disease, with a slowly progressive WM
involvement independent from motor functionality.<sup><xref ref-type="bibr" rid="bibr160-1756286419845567">160</xref></sup></p>
<p>Using VBM and rs-fMRI paradigms in nine patients with late-onset glycogenosis type
II, Barroni and colleagues revealed no significant difference in regional GM volumes
between patients and changes in brain connectivity in the salience network,
cingulate gyrus and medial frontal cortex, implicated in executive functioning. The
fMRI findings were congruent with neuropsychological impairment.<sup><xref ref-type="bibr" rid="bibr161-1756286419845567">161</xref></sup></p>
<sec id="section10-1756286419845567">
<title>Oculopharyngeal muscular dystrophy</title>
<p>OPMD is an adult-onset autosomal dominant disorder (onset is usually between the
fifth or sixth decade of life). It is characterized by progressive eyelid
drooping and proximal limb weakness (asymmetric). Pharyngeal muscle involvement
produces ptosis and dysphagia.<sup><xref ref-type="bibr" rid="bibr162-1756286419845567">162</xref></sup></p>
<p>Suspicion of OPMD is based on clinical criteria and the diagnosis is confirmed by
molecular genetic testing of <italic>PABPN1</italic>. In a few cases, CNS
involvement has been described and is associated with executive functions
impairment.</p>
<p>Quality of life is poor mainly because of significant dysphagia.<sup><xref ref-type="bibr" rid="bibr163-1756286419845567">163</xref></sup></p>
<p>Currently, no effective treatment exists for OPMD.</p>
<p>OPMD, described in a French-Canadian family for the first time, has the highest
prevalence among Bukhara Jews.<sup><xref ref-type="bibr" rid="bibr164-1756286419845567">164</xref></sup> OPMD is characterized by proximal limb and facial weakness, bilateral
ptosis, and dysphagia. It is a myopathy which affects all voluntary muscles and
in particular the levator palpebrae, tongue, pharynx, extraocular muscles. A CNS
involvement in OPMD has been suggested only in a few cases.<sup><xref ref-type="bibr" rid="bibr165-1756286419845567">165</xref></sup></p>
<p>Nevertheless, although few brain imaging studies are available, cognitive decline
and psychological disorders have been described in homozygous patients.<sup><xref ref-type="bibr" rid="bibr166-1756286419845567">166</xref></sup> Blumen and colleagues described 10 homozygous OPMD, detecting lacunar
infarcts and leukoaraiosis in a patient with cardiovascular risk factors and
brain atrophy.</p>
<p>Behavioral and psychological disturbances seem to correlate with the expansion
size in heterozygote OPMD.<sup><xref ref-type="bibr" rid="bibr167-1756286419845567">167</xref></sup></p>
<p>Recently, Chen and colleagues described 11 patients with a probable OPMD
diagnosis. Clinical phenotype was characterized by ocular pharyngeal muscle
weakness, severe brain involvement (cerebellum and brain stem were mildly
atrophied), and intrafamilial variability of muscle impairment. Nevertheless,
further molecular investigations are needed to understand the genetic background
and pathogenesis.<sup><xref ref-type="bibr" rid="bibr168-1756286419845567">168</xref></sup></p>
</sec>
<sec id="section11-1756286419845567">
<title>Facioscapulohumeral dystrophy</title>
<p>Facioscapulohumeral dystrophy (FSHD) is an autosomal dominant neuromuscular
disorder. It is characterized by (asymmetric) involvement of selective muscle
groups (face, shoulder, and arms) with a wide spectrum of phenotypic expression
and inter- and intrafamilial variability.<sup><xref ref-type="bibr" rid="bibr169-1756286419845567">169</xref></sup> It can be associated with CNS disorders. Previous studies reported
extra-muscular involvement and associations with hearing deficits, cardiac
complications, and schizophrenia.<sup><xref ref-type="bibr" rid="bibr170-1756286419845567">170</xref></sup> Epilepsy and mental retardation have been observed, even in the absence
of neuroradiological abnormalities, in patients with early onset FSHD.<sup><xref ref-type="bibr" rid="bibr171-1756286419845567">171</xref>,<xref ref-type="bibr" rid="bibr172-1756286419845567">172</xref></sup> Sporadic
association with multiple sclerosis has been reported.<sup><xref ref-type="bibr" rid="bibr173-1756286419845567">173</xref></sup> Fierro and colleagues described a relatively high incidence of WM
hyperintensities in the disease.<sup><xref ref-type="bibr" rid="bibr170-1756286419845567">170</xref></sup> In particular, WM hyperintense lesions were mainly located bilaterally in
parieto-temporal lobes in 44% of FSHD without a significant hemispheric
prevalence. No correlations between severity of WMHL, age, age at onset,
duration of the disease, or muscular impairment have been found.<sup><xref ref-type="bibr" rid="bibr170-1756286419845567">170</xref></sup> No cortical atrophy nor ventriculomegaly have been noted. Using
Transcranial magnetic stimulation (TMS), Di Lazzaro and colleagues observed a
significantly reduced intra-cortical inhibition in patients with FSHD compared
with healthy people, which may be due to a compensatory phenomenon of the
progressive muscle deficit. VBM analysis revealed clusters of GM volume
reduction in the left frontal lobe, in anterior cingulate and right frontopolar
cortex in the brain of patients with FSHD.<sup><xref ref-type="bibr" rid="bibr174-1756286419845567">174</xref></sup> The authors hypothesized that the volume loss of the left sensory-motor
area could be a consequence or cause of muscular weakness. Quarantelli and
colleagues, comparing 30 patients with 39 healthy controls, observed a
significant reduction of GM loss mainly in left frontal structures, precentral
cortex, the anterior cingulate cortex, and the right frontal region in patients
with FSHD and a correlation between GM and clinical severity. In particular,
three clusters of significant GM loss were detected: in the left precentral
cortex, anterior cingulate, and right frontopolar regions. WM hyperintensities
did not correlate with a more prominent GM loss<sup><xref ref-type="bibr" rid="bibr175-1756286419845567">175</xref></sup> and brain tissue volumes did not correlate with disease duration, size of
the genetic deletion, or age at onset.</p>
</sec>
</sec>
<sec id="section12-1756286419845567" sec-type="discussion">
<title>Discussion</title>
<p>Although NMDs refers to a heterogeneous group of disorders with different genetic and
phenotypic features many aspects of CNS neuromuscular involvement have been
observed. The pathogenic mechanisms involved in NMD brain damage are complex and
need further study. Significant progress has been made recently in the brain imaging
field. Nevertheless, the resulting data are still discordant and, until now, few
longitudinal studies are available on brain imaging changes. Future studies might
allow us to understand the pathogenesis of brain changes. We summarized the main
brain changes in <xref ref-type="table" rid="table2-1756286419845567">Table 2</xref>
with the principal imaging findings of CNS involvement in NMDs. We have focused on
congenital dystrophies, dystrophinopathies, dystroglycanopathies, myotonic
dystrophies, facio-scapulo-humeral dystrophy, and LGMD. Each pathology presents
typical features, but some common changes can be detected. Conventional MRI reveals
a more prominent involvement in the WM. In particular diffused, periventricular and
temporopolar, WM hyperintensities, and a thin corpus callosum were detected. Later,
the advancement of technology allowed the detection of GM alterations, with cortical
and subcortical involvement. In most of the papers assessed, observations on brain
involvement are associated with some clinically relevant guidelines for
psychological support and special schooling.</p>
<table-wrap id="table2-1756286419845567" orientation="portrait" position="float">
<label>Table 2.</label>
<caption>
<p>Summary of the main results of brain involvement in NMDs.</p>
</caption>
<alternatives>
<graphic xlink:href="10.1177_1756286419845567-table2"></graphic>
<table frame="hsides" rules="groups">
<colgroup span="1">
<col align="left" span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
<col align="char" char="." span="1"/>
</colgroup>
<thead>
<tr>
<th align="left" colspan="1" rowspan="1">Imaging<break></break>technique</th>
<th align="left" colspan="1" rowspan="1">DM1</th>
<th align="left" colspan="1" rowspan="1">DM2</th>
<th align="left" colspan="1" rowspan="1">LGMD</th>
<th align="left" colspan="1" rowspan="1">CMD</th>
<th align="left" colspan="1" rowspan="1">DMD</th>
<th align="left" colspan="1" rowspan="1">GSD II</th>
<th align="left" colspan="1" rowspan="1">OPMD</th>
<th align="left" colspan="1" rowspan="1">FSHD</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="1" rowspan="1">MRI</td>
<td colspan="1" rowspan="1">Ventricular enlargement</td>
<td colspan="1" rowspan="1">Ventricular enlargement</td>
<td colspan="1" rowspan="1">Ventricular enlargement</td>
<td colspan="1" rowspan="1">Ventricular enlargement</td>
<td colspan="1" rowspan="1">Ventricular enlargement</td>
<td colspan="1" rowspan="1">Ventricular enlargement</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Global atrophy (cortical and subcortical)<break></break>Thinner corpus
callosum<break></break>Dilated Virchow–Robin spaces<break></break>Temporopolar
WMHLs</td>
<td colspan="1" rowspan="1">Global atrophy</td>
<td colspan="1" rowspan="1">Global atrophy<break></break>(fronto-parieto cortex and
subcortical)<break></break>Dilated Virchow–Robin spaces and
subarachnoid space</td>
<td colspan="1" rowspan="1">Abnormalities in brain morphology<break></break>(gyration, cortical
sulci, fissures
alteration)<break></break>Agyria<break></break>Micropolygyria<break></break>Polymicrogyria<break></break>Cobblestone
lissencephaly<break></break>Hydrocephalus<break></break>Corpus callosum
agenesis</td>
<td colspan="1" rowspan="1">Subtle cortical atrophy</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Mild atrophy in cerebellum and brainstem<break></break>mild cortical
atrophy</td>
<td colspan="1" rowspan="1">Gray Matter reduction<break></break>Cortical (fronto
parietal)<break></break>Left &gt; right</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">WMHL (frontal and temporal lobes);<break></break>(ATWML)</td>
<td colspan="1" rowspan="1">Bilateral WMHL (periventricular, frontal parieto-occipital)</td>
<td colspan="1" rowspan="1">WMHL (periventricular and widespread)</td>
<td colspan="1" rowspan="1">Widespread WMHL</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Diffused WM abnormalities<break></break>WMHL (periventricular and
subcortical widespread)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Diffused WMHL (parietal-temporal lobes)</td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Gray matter reduction (VBM)<break></break>Cortical (all
lobes)<break></break>Subcortical (striatum, thalamus, nucleus
accumbens, cerebellum)</td>
<td colspan="1" rowspan="1">Gray matter reduction (VBM)<break></break>Cortical
(frontotemporal)<break></break>Subcortical (brainstem, thalamus,
hypothalamus, mesencephalon, int. pallidum, amygdala)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Grey matter volume reduction<break></break>(VBM)</td>
<td colspan="1" rowspan="1">Gray matter volume reduction (VBM)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">WM reduction (VBM)<break></break>Subcortical (all lobes)<break></break>Corpus
callosum<break></break>Fornix</td>
<td colspan="1" rowspan="1">WM reduction (VBM)<break></break>(Subcortical in all lobes, corpus
callosum,<break></break>cerebellum</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">DTI</td>
<td colspan="1" rowspan="1">Limbic system tracts<break></break>Association fibers (fornix, cingulum
bundle)<break></break>Corpus callosum<break></break>Projection
fibers<break></break>Cerebrum</td>
<td colspan="1" rowspan="1">Limbic system<break></break>Association fibers<break></break>Corpus
callosum</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">Diffused microstructural impairment, and in<break></break>occipital
lobe<break></break>Corpus callosum<break></break>Splenium</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">PET/SPECT/<break></break>fMRI</td>
<td colspan="1" rowspan="1">&lt;FDG uptake:<break></break>Cortical (fronto,
temporal)<break></break>Lentiform nucleus<break></break>&lt;
CBF:<break></break>Cortical (fronto temporal)<break></break>Hypothalamus</td>
<td colspan="1" rowspan="1">&lt;FDG uptake:<break></break>Cortical (fronto,
temporal<break></break>parietal operculum) Subcortical (Thalamus,
striatum)<break></break>&lt;CBF:<break></break>Cortical
(frontoparieto-occipital)</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1">&lt;FDG uptake:<break></break>medial temporal structures and cerebellum
and on the right side in sensorimotor and lateral
temporal<break></break>fMRI (rstate)<break></break>decrease of
synchronization</td>
<td colspan="1" rowspan="1">rs-fMRI<break></break>brain connectivity in salience network, cingulate
gyrus and medial frontal cortex</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
<tr>
<td colspan="1" rowspan="1">Ultrasound</td>
<td colspan="1" rowspan="1">Increased width of the third ventricle<break></break>Hyperechogenicity:
substantia nigra<break></break>Hypoechogenicity: brainstem raphe</td>
<td colspan="1" rowspan="1">Increased width of the third ventricle<break></break>Hyperechogenicity:
substantia nigra<break></break>Hypoechogenicity: brainstem raphe</td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
<td colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table>
</alternatives>
<table-wrap-foot>
<fn id="table-fn3-1756286419845567">
<p>ATWML, anterior temporal white matter hyperintense lesion; CBF, cerebral
blood flow; CMD, congenital muscular dystrophy; DM1, myotonic dystrophy
type 1; DM2, myotonic dystrophy type 2; DMD, Duchenne muscular
dystrophy; DTI, diffusion tensor imaging; FDG, F-fluorodeoxyglucose;
fMRI, functional magnetic resonance imaging; FSHD, facioscapulohumeral
dystrophy; GSD II, glycogenosis type II; LGMD, limb-girdle muscular
dystrophy; MRI, magnetic resonance imaging; OPMD, oculopharyngeal
muscular dystrophy; PET, positron emission tomography; rs-fMRI,
resting-State fMRI; SPECT, single photon emission computed tomography;
VBM, voxel-based morphometry; WM, white matter; WMHL, White Matter
Hyperintense Load in the table.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Clinical observations revealed some intellectual impairment in a number of NMDs, as
well as difficulties in reasoning and memory. Congenital onset cases seem to be more
affected than adult-onset forms and exhibit pronounced WM abnormalities and
sometimes epilepsy. Cognitive impairment has been found in most patients with
dystrophinopathy, who usually have difficulty with abstract reasoning and
calculation. Myotonic dystrophy showed cortical atrophy, a mild form of intellectual
impairment and behavioral abnormalities. There is evidence of MRI abnormalities of
both WM and GM. In a preliminary longitudinal study, cognitive abnormalities appear
not to be progressive. We also compared neuroimaging abnormalities in LGMD 2I and in
other dystroglycanopathy in relation to the age of disease onset. Nevertheless,
until now, the evolution of brain involvement and the correlation with clinical
symptomatology is still unclear, and few follow-up studies have been published.
Regarding pathomechanisms, there are a number of membrane protein complexes (i.e.
dystroglycan complex and sarcoglycan complex) that are signaling at the surface of
membrane in both muscle and neuron. Therefore, lack of integrity of the sarcolemmal
membrane or neuronal membrane leads both to the dysfunction of neurons and muscle
and possible reactive inflammation by microglia and macrophages. An important
clinical issue is to advise when imaging techniques are required in muscular
patients. In our opinion, these techniques are useful not only for diagnosis but
also as an indication in the follow up of patients, especially in children. In adult
cases, cognitive behavioral therapy may be used in the follow up of DM1 cases.
Presymptomatic behavioral abnormalities such as mood disorders should be screened
before open depression or mood disorders might influence negatively quality of life
of patients and caregivers.</p>
<sec id="section13-1756286419845567">
<title>Future prospective and limitations</title>
<p>Our review suggested that only ventricular enlargement with hydrocephalus are in
most cases related to mental retardation. Supra-tentorial and subcortical WM
changes might determine a less frequent and milder cognitive abnormality.
Accurate histological, immunohistochemical and biochemical evaluations are
needed in the brain as well as autoptic studies. An evaluation of 3.0 T MRI and
DTI tractography with relation to default connectivity might lead to a better
understanding of the pathomechanism of brain abnormalities. Another technique
that could evaluate the dysfunctional disease mechanism is the level of oxygen
perfusion in the brain by arterial spin labeling (ASL) MRI, an alternative to
expensive and invasive PET. ASL is so far been used in the heart and is
applicable to the brain to study the energetic state of neurons since this
tissue is highly perfused.<sup><xref ref-type="bibr" rid="bibr176-1756286419845567">176</xref>,<xref ref-type="bibr" rid="bibr177-1756286419845567">177</xref></sup> A multidisciplinary
approach of patients with NMDs with brain involvement or mental retardation is
needed. Medical and paramedical personnel to be involved in the team are
neurologists, psychologists, neuropsychologists, neuroradiologists, physical
therapists, occupational therapists, and social workers. Caregivers can also be
supported by such teams. Another important point is that new innovative
therapies used in glycogenosis type 2 (ERT in combination with chaperon) or
ANTISENSE OLIGONUCLEOTIDES in DMD, possibly available in the future for myotonic
dystrophy, need to cross the brain–blood barrier (BBB). In fact, most of the new
treatments do not cross the BBB. In Pompe disease, the lack of penetration can
cause permanent dysfunction in surviving children with Pompe that present facial
abnormalities and respiratory difficulties. Therefore, while motor skills may be
improved, intellectual functions might be impaired and not changed with ERT.</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding:</bold> This research received no specific grant from any funding agency in the public,
commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="COI-statement">
<p><bold>Conflict of interest statement:</bold> The authors declare that there is no conflict of interest.</p>
</fn>
<fn fn-type="other">
<p><bold>ORCID iD:</bold> Corrado Angelini <inline-graphic xlink:href="10.1177_1756286419845567-img1.jpg"></inline-graphic>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-9554-8794">https://orcid.org/0000-0002-9554-8794</ext-link></p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1756286419845567">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>D’Angelo</surname><given-names>MG</given-names></name><name><surname>Bresolin</surname><given-names>N.</given-names></name></person-group>
<article-title>Report of the 95th European Neuromuscular Centre (ENMC) sponsored
International Workshop Cognitive Impairment in Neuromuscular Disorders,
Naarden, The Netherlands, 13–15 July 2001</article-title>.
<source/>Neuromuscul Disord
<year>2003</year>; <volume>13</volume>:
<fpage>72</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="pmid">12467736</pub-id></mixed-citation>
</ref>
<ref id="bibr2-1756286419845567">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wahlund</surname><given-names>LO</given-names></name><name><surname>Barkhof</surname><given-names>F</given-names></name><name><surname>Fazekas</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>A new rating scale for age-related white matter
changes</article-title>. <source/>Stroke
<year>2001</year>; <volume>32</volume>:
<fpage>1318</fpage>–<lpage>1322</lpage>.<pub-id pub-id-type="pmid">11387493</pub-id></mixed-citation>
</ref>
<ref id="bibr3-1756286419845567">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ashburner</surname><given-names>J</given-names></name><name><surname>Friston</surname><given-names>KJ.</given-names></name></person-group>
<article-title>Voxel-based morphometry—the methods</article-title>.
<source/>NeuroImage
<year>2000</year>; <volume>11</volume>:
<fpage>805</fpage>–<lpage>821</lpage>.<pub-id pub-id-type="pmid">10860804</pub-id></mixed-citation>
</ref>
<ref id="bibr4-1756286419845567">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fischl</surname><given-names>B</given-names></name><name><surname>Dale</surname><given-names>AM.</given-names></name></person-group>
<article-title>Measuring the thickness of the human cerebral cortex from
magnetic resonance images</article-title>. <source/>Proc Natl Acad Sci
USA
<year>2000</year>; <volume>97</volume>:
<fpage>11050</fpage>–<lpage>11055</lpage>.<pub-id pub-id-type="pmid">10984517</pub-id></mixed-citation>
</ref>
<ref id="bibr5-1756286419845567">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beaulieu</surname><given-names>C.</given-names></name></person-group>
<article-title>The basis of anisotropic water diffusion in the nervous system -
a technical review</article-title>. <source/>NMR Biomed
<year>2002</year>; <volume>15</volume>:
<fpage>435</fpage>–<lpage>455</lpage>.<pub-id pub-id-type="pmid">12489094</pub-id></mixed-citation>
</ref>
<ref id="bibr6-1756286419845567">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mori</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>J.</given-names></name></person-group>
<article-title>Principles of diffusion tensor imaging and its applications to
basic neuroscience research</article-title>. <source/>Neuron
<year>2006</year>; <volume>51</volume>:
<fpage>527</fpage>–<lpage>539</lpage>.<pub-id pub-id-type="pmid">16950152</pub-id></mixed-citation>
</ref>
<ref id="bibr7-1756286419845567">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abhinav</surname><given-names>K</given-names></name><name><surname>Yeh</surname><given-names>FC</given-names></name><name><surname>Pathak</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Advanced diffusion MRI fiber tracking in
neurosurgical and neurodegenerative disorders and neuroanatomical studies: a
review</article-title>. <source/>Biochim Biophys Acta
<year>2014</year>; <volume>1842</volume>:
<fpage>2286</fpage>–<lpage>2297</lpage>.<pub-id pub-id-type="pmid">25127851</pub-id></mixed-citation>
</ref>
<ref id="bibr8-1756286419845567">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Beckmann</surname><given-names>F</given-names></name><name><surname>Smith</surname><given-names>S.</given-names></name></person-group>
<article-title>Probabilistic independent component analysis for functional
magnetic resonance imaging</article-title>. <source/>IEEE Trans Med
Imaging
<year>2004</year>; <volume>23</volume>:
<fpage>137</fpage>–<lpage>152</lpage>.<pub-id pub-id-type="pmid">14964560</pub-id></mixed-citation>
</ref>
<ref id="bibr9-1756286419845567">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Smith</surname><given-names>SM</given-names></name><name><surname>Jenkinson</surname><given-names>M</given-names></name><name><surname>Woolrich</surname><given-names>MW</given-names></name><etal>et al</etal></person-group>
<article-title>Advances in functional and structural MR image
analysis and implementation as FSL</article-title>.
<source/>NeuroImage
<year>2004</year>; <volume>23</volume>:
<fpage>208</fpage>–<lpage>219</lpage>.</mixed-citation>
</ref>
<ref id="bibr10-1756286419845567">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Logothetis</surname><given-names>NK.</given-names></name></person-group>
<article-title>What we can do and what we cannot do with fMRI</article-title>.
<source/>Nature
<year>2008</year>; <volume>453</volume>:
<fpage>869</fpage>–<lpage>878</lpage>.<pub-id pub-id-type="pmid">18548064</pub-id></mixed-citation>
</ref>
<ref id="bibr11-1756286419845567">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wintermark</surname><given-names>M</given-names></name><name><surname>Sesay</surname><given-names>M</given-names></name><name><surname>Barbier</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Comparative overview of brain perfusion imaging
techniques</article-title>. <source/>Stroke
<year>2005</year>; <volume>36</volume>:
<fpage>e83</fpage>–<lpage>e99</lpage>.<pub-id pub-id-type="pmid">16100027</pub-id></mixed-citation>
</ref>
<ref id="bibr12-1756286419845567">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Warwick</surname><given-names>JM.</given-names></name></person-group>
<article-title>Imaging of brain function using SPECT</article-title>.
<source/>Metab Brain Dis
<year>2004</year>; <fpage>113</fpage>–<lpage>123</lpage>.<pub-id pub-id-type="pmid">15214511</pub-id></mixed-citation>
</ref>
<ref id="bibr13-1756286419845567">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Roggendorf</surname><given-names>W</given-names></name><name><surname>Schroder</surname><given-names>U</given-names></name><etal>et al</etal></person-group>
<article-title>Echogenicity of the substantia
Nigra</article-title>. <source/>Arch Neurol
<year>2002</year>; <volume>59</volume>:
<fpage>999</fpage>–<lpage>1005</lpage>.<pub-id pub-id-type="pmid">12056937</pub-id></mixed-citation>
</ref>
<ref id="bibr14-1756286419845567">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walter</surname><given-names>MC</given-names></name><name><surname>Lochmüller</surname><given-names>H.</given-names></name></person-group>
<article-title>Muscular dystrophies</article-title>. <source/>Neurol Clin
Neurosci
<year>2007</year>; <volume>85</volume>(<issue>15</issue>):
<fpage>1142</fpage>–<lpage>1167</lpage>.</mixed-citation>
</ref>
<ref id="bibr15-1756286419845567">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Falsaperla</surname><given-names>R</given-names></name><name><surname>Praticò</surname><given-names>AD</given-names></name><name><surname>Ruggieri</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Congenital muscular dystrophy: from muscle to
brain</article-title>. <source/>Ital J Pediatr; <year>2016</year>;
<volume>42</volume>(<issue>1</issue>): <fpage>78</fpage> Epub ahead of
print 31 August 2016. DOI: <pub-id pub-id-type="doi">10.1186/s13052-016-0289-9</pub-id>.<pub-id pub-id-type="pmid">27576556</pub-id></mixed-citation>
</ref>
<ref id="bibr16-1756286419845567">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bucelli</surname><given-names>RC</given-names></name><name><surname>Arhzaouy</surname><given-names>K</given-names></name><name><surname>Pestronk</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>SQSTM1 splice site mutation in distal myopathy
with rimmed vacuoles</article-title>. <source/>Neurology
<year>2015</year>; <volume>85</volume>:
<fpage>665</fpage>–<lpage>674</lpage>.<pub-id pub-id-type="pmid">26208961</pub-id></mixed-citation>
</ref>
<ref id="bibr17-1756286419845567">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lin</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Lin</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>New insights into genotype - phenotype
correlations in Chinese facioscapulohumeral muscular dystrophy: a
retrospective analysis of 178 patients</article-title>. <source/>Chin Med
J; <volume>128</volume>(<issue>13</issue>):
<fpage>1707</fpage>–<lpage>1713</lpage>. Epub ahead of print 2015. DOI:
<pub-id pub-id-type="doi">10.4103/0366-6999.159336</pub-id>.</mixed-citation>
</ref>
<ref id="bibr18-1756286419845567">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Hunt</surname><given-names>SD</given-names></name><name><surname>Matthias</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>Lab Resource: stem cell line generation of an
induced pluripotent stem cell line (CSCRMi001-A) from a patient with a new
type of limb-girdle muscular dystrophy (LGMD) due to a missense mutation in
POGLUT1 (Rumi)</article-title>. <source/>Stem Cell Res
<year>2017</year>; <volume>24</volume>:
<fpage>102</fpage>–<lpage>105</lpage>.<pub-id pub-id-type="pmid">29034878</pub-id></mixed-citation>
</ref>
<ref id="bibr19-1756286419845567">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Santoro</surname><given-names>M</given-names></name><name><surname>Masciullo</surname><given-names>M</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>Myotonic dystrophy type 1: role of CCG, CTC and
CGG interruptions within DMPK alleles in the pathogenesis and molecular
diagnosis</article-title>. <source/>Clin Genet
<year>2017</year>; <volume>92</volume>:
<fpage>355</fpage>–<lpage>364</lpage>.<pub-id pub-id-type="pmid">27991661</pub-id></mixed-citation>
</ref>
<ref id="bibr20-1756286419845567">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hamilton</surname><given-names>MJ</given-names></name><name><surname>Mclean</surname><given-names>J</given-names></name><name><surname>Cumming</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Outcome measures for central nervous system
evaluation in myotonic dystrophy type 1 may be confounded by deficits in
motor function or insight</article-title>. <source/>Front Neurol;
<year>2018</year>; <volume>9</volume>: <fpage>780</fpage> Epub ahead of
print 2018. DOI: <pub-id pub-id-type="doi">10.3389/fneur.2018.00780</pub-id>.<pub-id pub-id-type="pmid">30333784</pub-id></mixed-citation>
</ref>
<ref id="bibr21-1756286419845567">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brockington</surname><given-names>M</given-names></name><name><surname>Yuva</surname><given-names>Y</given-names></name><name><surname>Prandini</surname><given-names>P</given-names></name><etal>et al</etal></person-group>
<article-title>Mutations in the fukutin-related protein gene
(FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic
variant of congenital muscular dystrophy MDC1C</article-title>. <source/>Hum
Mol Genet
<year>2001</year>; <volume>10</volume>:
<fpage>2851</fpage>–<lpage>2860</lpage>.<pub-id pub-id-type="pmid">11741828</pub-id></mixed-citation>
</ref>
<ref id="bibr22-1756286419845567">
<label>22</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Pegoraro</surname><given-names>E</given-names></name><name><surname>Hoffman</surname><given-names>EP.</given-names></name></person-group>
<article-title>Limb-girdle muscular dystrophy overview</article-title>. In:
<person-group person-group-type="editor"><name><surname>Pagon</surname><given-names>RA</given-names></name><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Dolan</surname><given-names>CR</given-names></name><etal>et al</etal></person-group>, (eds). <source/>GeneReviews [Internet].
<publisher-loc>Seattle, WA</publisher-loc>: <publisher-name>University of
Washington</publisher-name>; <year>1993</year>
<ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK1408/">http://www.ncbi.nlm.nih.gov/books/NBK1408/</ext-link>. Updated August 30,
2012. <comment>Accessed 2012</comment>.</mixed-citation>
</ref>
<ref id="bibr23-1756286419845567">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bourteel</surname><given-names>H</given-names></name><name><surname>Vermersch</surname><given-names>P</given-names></name><name><surname>Cuisset</surname><given-names>JM</given-names></name><etal>et al</etal></person-group>
<article-title>Clinical and mutational spectrum of limb-girdle
muscular dystrophy type 2I in 11 French patients</article-title>. <source/>J
Neurol Neurosurg Psychiatry
<year>2009</year>; <volume>80</volume>:
<fpage>1405</fpage>–<lpage>1408</lpage>.<pub-id pub-id-type="pmid">19917824</pub-id></mixed-citation>
</ref>
<ref id="bibr24-1756286419845567">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gavassini</surname><given-names>BF</given-names></name><name><surname>Carboni</surname><given-names>N</given-names></name><name><surname>Nielsen</surname><given-names>JE</given-names></name><etal>et al</etal></person-group>
<article-title>Clinical and molecular characterization of
limb-girdle muscular dystrophy due to LAMA2 mutations</article-title>.
<source/>Muscle Nerve
<year>2011</year>; <volume>44</volume>:
<fpage>703</fpage>–<lpage>709</lpage>.<pub-id pub-id-type="pmid">21953594</pub-id></mixed-citation>
</ref>
<ref id="bibr25-1756286419845567">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Godfrey</surname><given-names>C</given-names></name><name><surname>Escolar</surname><given-names>D</given-names></name><name><surname>Brockington</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Fukutin gene mutations in steroid-responsive
limb girdle muscular dystrophy</article-title>. <source/>Ann Neurol
<year>2006</year>; <volume>60</volume>:
<fpage>603</fpage>–<lpage>610</lpage>.<pub-id pub-id-type="pmid">17044012</pub-id></mixed-citation>
</ref>
<ref id="bibr26-1756286419845567">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Østergaard</surname><given-names>ST</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name><name><surname>Stojkovic</surname><given-names>T</given-names></name><etal>et al</etal></person-group>
<article-title>Limb girdle muscular dystrophy due to
mutations</article-title> in <source/>POMT2. J Neurol Neurosurg
Psychiatry
<year>2018</year>; <volume>89</volume>:
<fpage>506</fpage>–<lpage>512</lpage>.<pub-id pub-id-type="pmid">29175898</pub-id></mixed-citation>
</ref>
<ref id="bibr27-1756286419845567">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Godfrey</surname><given-names>C</given-names></name><name><surname>Clement</surname><given-names>ÃE</given-names></name><name><surname>Mein</surname><given-names>ÃR</given-names></name><etal>et al</etal></person-group>
<article-title>Refining genotype phenotype correlations in
muscular dystrophies with defective glycosylation of
dystroglycan</article-title>. <source/>Brain. Epub ahead of print 18
September 2007;130(Pt 10): 2725–35. DOI: <pub-id pub-id-type="doi">10.1093/brain/awm212</pub-id>.</mixed-citation>
</ref>
<ref id="bibr28-1756286419845567">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lommel</surname><given-names>M</given-names></name><name><surname>Hermann</surname><given-names>R</given-names></name><name><surname>Uyanik</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>Correlation of enzyme activity and clinical
phenotype in POMT1- associated dystroglycanopathies</article-title>.
<source/>Neurology
<year>2010</year>; <volume>74</volume>:
<fpage>157</fpage>–<lpage>164</lpage>.<pub-id pub-id-type="pmid">20065251</pub-id></mixed-citation>
</ref>
<ref id="bibr29-1756286419845567">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Parano</surname><given-names>E</given-names></name><name><surname>Fiumara</surname><given-names>A</given-names></name><name><surname>Falsperla</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>Congenital muscular dystrophy: correlation of
muscle biopsy and clinical features</article-title>. <source/>Pediatr
Neurol
<year>1994</year>; <volume>10</volume>:
<fpage>233</fpage>–<lpage>236</lpage>.<pub-id pub-id-type="pmid">8060426</pub-id></mixed-citation>
</ref>
<ref id="bibr30-1756286419845567">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bönnemann</surname><given-names>CG</given-names></name><name><surname>Wang</surname><given-names>CH</given-names></name><name><surname>Quijano-Roy</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Diagnostic approach to the congenital muscular
dystrophies</article-title>. <source/>Neuromuscul Disord
<year>2014</year>; <volume>24</volume>:
<fpage>289</fpage>–<lpage>311</lpage>.<pub-id pub-id-type="pmid">24581957</pub-id></mixed-citation>
</ref>
<ref id="bibr31-1756286419845567">
<label>31</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Voit</surname><given-names>T</given-names></name><name><surname>Tomè</surname><given-names>F.</given-names></name></person-group>
<article-title>The congenital muscular dystrophies</article-title>. In:
<person-group person-group-type="editor"><name><surname>Engel</surname><given-names>AG</given-names></name><name><surname>Franzini-Amstrong</surname><given-names>C</given-names></name></person-group> (eds) <source/>Myology-basic and clinical. <edition>3rd
ed.</edition>
<publisher-loc>New York</publisher-loc>: <publisher-name>McGraw-Hill-Medical
Publishing Division</publisher-name>, <year>2004</year>,
pp.<fpage>1203</fpage>–<lpage>1238</lpage>.</mixed-citation>
</ref>
<ref id="bibr32-1756286419845567">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Angelini</surname><given-names>C.</given-names></name></person-group>
<article-title>Enzyme replacement therapy for the treatment of Pompe
disease</article-title>. <source/>Expert Opin Orphan Drugs
<year>2018</year>; <volume>6</volume>:
<fpage>311</fpage>–<lpage>318</lpage>.</mixed-citation>
</ref>
<ref id="bibr33-1756286419845567">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fukuyama</surname><given-names>Y</given-names></name><name><surname>Osawa</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>H.</given-names></name></person-group>
<article-title>Congenital progressive muscular dystrophy of the fukuyama type -
clinical, genetic and pathological considerations</article-title>.
<source/>Brain Dev
<year>1981</year>; <volume>3</volume>:
<fpage>1</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="pmid">7258547</pub-id></mixed-citation>
</ref>
<ref id="bibr34-1756286419845567">
<label>34</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kamoshita</surname><given-names>S.</given-names></name></person-group>
<article-title>Etiology of congenital muscular dystrophy (Fukuyama
type)</article-title>. <source/>Nihon Rinsho
<year>1977</year>; <volume>35</volume>:
<fpage>3929</fpage>–<lpage>3935</lpage>.<pub-id pub-id-type="pmid">599674</pub-id></mixed-citation>
</ref>
<ref id="bibr35-1756286419845567">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Barkovich</surname><given-names>AJ.</given-names></name></person-group>
<article-title>Neuroimaging manifestations and classification of congenital
muscular dystrophies</article-title>. <source/>Am J Neuroradiol
<year>1998</year>; <volume>19</volume>:
<fpage>1389</fpage>–<lpage>1396</lpage>.<pub-id pub-id-type="pmid">9763366</pub-id></mixed-citation>
</ref>
<ref id="bibr36-1756286419845567">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toda</surname><given-names>T</given-names></name><name><surname>Segawa</surname><given-names>M</given-names></name><name><surname>Nomura</surname><given-names>Y</given-names></name><etal>et al</etal></person-group>
<article-title>Localization of a gene for Fukuyama type
congenital muscular dystrophy to chromosome 9q31−33</article-title>.
<source/>Nat Genet
<year>1993</year>; <volume>5</volume>:
<fpage>283</fpage>–<lpage>286</lpage>.<pub-id pub-id-type="pmid">8275093</pub-id></mixed-citation>
</ref>
<ref id="bibr37-1756286419845567">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hehr</surname><given-names>U</given-names></name><name><surname>Uyanik</surname><given-names>G</given-names></name><name><surname>Gross</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Novel POMGnT1 mutations define broader
phenotypic spectrum of muscle-eye-brain disease</article-title>.
<source/>Neurogenetics
<year>2007</year>; <volume>8</volume>:
<fpage>279</fpage>–<lpage>288</lpage>.<pub-id pub-id-type="pmid">17906881</pub-id></mixed-citation>
</ref>
<ref id="bibr38-1756286419845567">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yiş</surname><given-names>U</given-names></name><name><surname>Uyanik</surname><given-names>G</given-names></name><name><surname>Rosendahl</surname><given-names>DM</given-names></name><etal>et al</etal></person-group>
<article-title>Clinical, radiological, and genetic survey of
patients with muscle-eye-brain disease caused by mutations in
POMGNT1</article-title>. <source/>Pediatr Neurol
<year>2014</year>; <volume>50</volume>:
<fpage>491</fpage>–<lpage>497</lpage>.<pub-id pub-id-type="pmid">24731844</pub-id></mixed-citation>
</ref>
<ref id="bibr39-1756286419845567">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Devisme</surname><given-names>L</given-names></name><name><surname>Bouchet</surname><given-names>C</given-names></name><name><surname>Gonzals</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Cobblestone lissencephaly: neuropathological
subtypes and correlations with genes of
dystroglycanopathies</article-title>. <source/>Brain
<year>2012</year>; <volume>135</volume>:
<fpage>469</fpage>–<lpage>482</lpage>.<pub-id pub-id-type="pmid">22323514</pub-id></mixed-citation>
</ref>
<ref id="bibr40-1756286419845567">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dobyns</surname><given-names>WB</given-names></name><name><surname>Patton</surname><given-names>MA</given-names></name><name><surname>Stratton</surname><given-names>RF</given-names></name><etal>et al</etal></person-group>
<article-title>Cobblestone lissencephaly with normal eyes and
muscle</article-title>. <source/>Neuropediatrics
<year>1996</year>; <volume>27</volume>:
<fpage>70</fpage>–<lpage>75</lpage>.<pub-id pub-id-type="pmid">8737821</pub-id></mixed-citation>
</ref>
<ref id="bibr41-1756286419845567">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baldanzi</surname><given-names>S</given-names></name><name><surname>Cecchi</surname><given-names>P</given-names></name><name><surname>Fabbri</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Relationship between neuropsychological
impairment and grey and white matter changes in adult-onset myotonic
dystrophy type 1</article-title>. <source/>NeuroImage Clin
<year>2016</year>; <volume>12</volume>:
<fpage>190</fpage>–<lpage>197</lpage>.<pub-id pub-id-type="pmid">27437180</pub-id></mixed-citation>
</ref>
<ref id="bibr42-1756286419845567">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Harper</surname><given-names>PS.</given-names></name></person-group>
<article-title>Congenital myotonic dystrophy in Britain: I. Clinical
aspects</article-title>. <source/>Arch Dis Child
<year>1975</year>; <volume>50</volume>:
<fpage>505</fpage>–<lpage>513</lpage>.<pub-id pub-id-type="pmid">1101835</pub-id></mixed-citation>
</ref>
<ref id="bibr43-1756286419845567">
<label>43</label>
<mixed-citation publication-type="journal">
<collab>The International Myotonic Dystrophy Consortium (IDMC)</collab>.
<article-title>New nomenclature and DNA testing guidelines for myotonic
dystrophy type 1 (DM1)</article-title>. <source/>Neurology
<year>2000</year>; <volume>54</volume>:
<fpage>1218</fpage>–<lpage>1221</lpage>.<pub-id pub-id-type="pmid">10746587</pub-id></mixed-citation>
</ref>
<ref id="bibr44-1756286419845567">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>De Antonio</surname><given-names>M</given-names></name><name><surname>Dogan</surname><given-names>C</given-names></name><name><surname>Hamroun</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Unravelling the myotonic dystrophy type 1
clinical spectrum: a systematic registry-based study with implications for
disease classification</article-title>. <source/>Rev Neurol
<year>2016</year>; <volume>172</volume>:
<fpage>572</fpage>–<lpage>580</lpage>.<pub-id pub-id-type="pmid">27665240</pub-id></mixed-citation>
</ref>
<ref id="bibr45-1756286419845567">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Modoni</surname><given-names>D</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Pomponi</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Characterization of the pattern of cognitive
impairment in myotonic dystrophy type 1</article-title>. <source/>Arch
Neuro
<year>2004</year>; <volume>61</volume>:
<fpage>1</fpage>–<lpage>5</lpage>.</mixed-citation>
</ref>
<ref id="bibr46-1756286419845567">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ekstrom</surname><given-names>A</given-names></name><name><surname>Hakenas-Plate</surname><given-names>L</given-names></name><name><surname>Samuelsson</surname><given-names>L</given-names></name><etal>et al</etal></person-group>
<article-title>Autism spectrum conditions in myotonic dystrophy
type 1: a study on 57 individuals with congenital and childhood
forms</article-title>. <source/>Am J Med Genet B Neuropsychiatr
Genet
<year>2008</year>; <volume>926</volume>:
<fpage>918</fpage>–<lpage>926</lpage>.</mixed-citation>
</ref>
<ref id="bibr47-1756286419845567">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caso</surname><given-names>F</given-names></name><name><surname>Agosta</surname><given-names>F</given-names></name><name><surname>Peric</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Cognitive impairment in myotonic dystrophy type
1 is associated with white matter damage</article-title>. <source/>PLoS
One; <volume>9</volume> Epub ahead of print 2014; 9(8):e104697.
DOI: <pub-id pub-id-type="doi">10.1371/journal.pone.0104697</pub-id>.</mixed-citation>
</ref>
<ref id="bibr48-1756286419845567">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cabada</surname><given-names>T</given-names></name><name><surname>Iridoy</surname><given-names>M</given-names></name><name><surname>Jericó</surname><given-names>I</given-names></name><etal>et al</etal></person-group>
<article-title>Brain involvement in myotonic dystrophy type 1:
a morphometric and diffusion tensor imaging study with neuropsychological
correlation</article-title>. <source/>Arch Clin Neuropsychol
<year>2017</year>; <volume>32</volume>:
<fpage>401</fpage>–<lpage>412</lpage>.<pub-id pub-id-type="pmid">28164212</pub-id></mixed-citation>
</ref>
<ref id="bibr49-1756286419845567">
<label>49</label>
<mixed-citation publication-type="confproc">
<person-group person-group-type="author"><name><surname>Bosco</surname><given-names>G</given-names></name><name><surname>Diamanti</surname><given-names>S</given-names></name><name><surname>Meola</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>Workshop report: consensus on biomarkers of
cerebral involvement in myotonic dystrophy</article-title>, <conf-date>2-3
December 2014</conf-date>, <conf-loc>Milan, Italy</conf-loc>
<conf-name>Neuromuscul Disord</conf-name>
<year>2015</year>; <volume>25</volume>:
<fpage>813</fpage>–<lpage>823</lpage>.</mixed-citation>
</ref>
<ref id="bibr50-1756286419845567">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gourdon</surname><given-names>G</given-names></name><name><surname>Meola</surname><given-names>G.</given-names></name></person-group>
<article-title>Myotonic dystrophies: state of the art of new therapeutic
developments for the CNS</article-title>. <source/>Front Cell
Neurosci; <volume>11</volume> Epub ahead of print 2017; 11:101.
DOI: <pub-id pub-id-type="doi">10.3389/fncel.2017.00101</pub-id>.</mixed-citation>
</ref>
<ref id="bibr51-1756286419845567">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meola</surname><given-names>G</given-names></name><name><surname>Sansone</surname><given-names>V.</given-names></name></person-group>
<article-title>Cerebral involvement in myotonic dystrophies</article-title>.
<source/>Muscle Nerve
<year>2007</year>; <volume>36</volume>:
<fpage>294</fpage>–<lpage>306</lpage>.<pub-id pub-id-type="pmid">17486579</pub-id></mixed-citation>
</ref>
<ref id="bibr52-1756286419845567">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weber</surname><given-names>YG</given-names></name><name><surname>Roebling</surname><given-names>R</given-names></name><name><surname>Kassubek</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Comparative analysis of brain structure,
metabolism, and cognition in myotonic dystrophy 1 and 2</article-title>.
<source/>Neurology
<year>2010</year>; <volume>74</volume>:
<fpage>1108</fpage>–<lpage>1117</lpage>.<pub-id pub-id-type="pmid">20220122</pub-id></mixed-citation>
</ref>
<ref id="bibr53-1756286419845567">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Baldanzi</surname><given-names>S</given-names></name><name><surname>Bevilacqua</surname><given-names>F</given-names></name><name><surname>Lorio</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>Disease awareness in myotonic dystrophy type 1:
an observational cross-sectional study</article-title>. <source/>Orphanet J
Rare Dis; <volume>11</volume> Epub ahead of print 2016;11: 34.
DOI: <pub-id pub-id-type="doi">10.1186/s13023-016-0417-z</pub-id>.</mixed-citation>
</ref>
<ref id="bibr54-1756286419845567">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sansone</surname><given-names>V</given-names></name><name><surname>Gandossini</surname><given-names>S</given-names></name><name><surname>Cotelli</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Cognitive impairment in adult myotonic
dystrophies: a longitudinal study</article-title>. <source/>Neurol
Sci
<year>2007</year>; <volume>28</volume>:
<fpage>9</fpage>–<lpage>15</lpage>.<pub-id pub-id-type="pmid">17385090</pub-id></mixed-citation>
</ref>
<ref id="bibr55-1756286419845567">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Modoni</surname><given-names>A</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Vita</surname><given-names>MG</given-names></name><etal>et al</etal></person-group>
<article-title>Cognitive impairment in myotonic dystrophy type
1 (DM1): a longitudinal follow-up study</article-title>. <source/>J
Neurol
<year>2008</year>; <volume>255</volume>:
<fpage>1737</fpage>–<lpage>1742</lpage>.<pub-id pub-id-type="pmid">18821050</pub-id></mixed-citation>
</ref>
<ref id="bibr56-1756286419845567">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Winblad</surname><given-names>S</given-names></name><name><surname>Samuelsson</surname><given-names>L</given-names></name><name><surname>Lindberg</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Cognition in myotonic dystrophy type 1: a 5-year
follow-up study</article-title>. <source/>Eur J Neurol
<year>2016</year>; <volume>23</volume>:
<fpage>1471</fpage>–<lpage>1476</lpage>.<pub-id pub-id-type="pmid">27323306</pub-id></mixed-citation>
</ref>
<ref id="bibr57-1756286419845567">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peric</surname><given-names>S</given-names></name><name><surname>Rakocevic</surname><given-names>V</given-names></name><name><surname>Gorana</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Clusters of cognitive impairment among different
phenotypes of myotonic dystrophy type 1 and type 2</article-title>.
<source/>Neurol Sci
<year>2017</year>; <volume>38</volume>:
<fpage>415</fpage>–<lpage>423</lpage>.<pub-id pub-id-type="pmid">27896491</pub-id></mixed-citation>
</ref>
<ref id="bibr58-1756286419845567">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Di Costanzo</surname><given-names>A</given-names></name><name><surname>Di Salle</surname><given-names>F</given-names></name><name><surname>Santoro</surname><given-names>L</given-names></name><etal>et al</etal></person-group>
<article-title>Dilated Virchow–Robin spaces in myotonic
dystrophy: frequency, extent and significance</article-title>. <source/>Eur
Neurol
<year>2001</year>; <volume>46</volume>:
<fpage>131</fpage>–<lpage>139</lpage>.<pub-id pub-id-type="pmid">11598331</pub-id></mixed-citation>
</ref>
<ref id="bibr59-1756286419845567">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bird</surname><given-names>TD</given-names></name><name><surname>Follett</surname><given-names>C</given-names></name><name><surname>Griep</surname><given-names>E.</given-names></name></person-group>
<article-title>Cognitive and personality function in myotonic muscular
dystrophy</article-title>. <source/>J Neurol Neurosurg Psychiatry
<year>1983</year>; <volume>46</volume>:
<fpage>971</fpage>–<lpage>980</lpage>.<pub-id pub-id-type="pmid">6655483</pub-id></mixed-citation>
</ref>
<ref id="bibr60-1756286419845567">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pires</surname><given-names>M</given-names></name><name><surname>Nunes</surname><given-names>B</given-names></name><name><surname>Monteiro</surname><given-names>L.</given-names></name></person-group>
<article-title>Computed tomographic findings of brain and skull in myotonic
dystrophy</article-title>. <source/>J Neurol Neurosurg Psychiatry
<year>1987</year>; <volume>50</volume>:
<fpage>1387</fpage>–<lpage>1388</lpage>.</mixed-citation>
</ref>
<ref id="bibr61-1756286419845567">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cornacchia</surname><given-names>L</given-names></name><name><surname>Marina</surname><given-names>R</given-names></name><name><surname>Ballarini</surname><given-names>V</given-names></name><etal>et al</etal></person-group>
<article-title>Computed tomographic findings of brain and skull
in myotonic dystrophy</article-title>. <source/>J Neurol Neurosurg
Psychiatry
<year>1988</year>; <volume>51</volume>:
<fpage>1463</fpage>–<lpage>1464</lpage>.<pub-id pub-id-type="pmid">3236032</pub-id></mixed-citation>
</ref>
<ref id="bibr62-1756286419845567">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Walker</surname><given-names>G</given-names></name><name><surname>Rosser</surname><given-names>R</given-names></name><name><surname>Mastaglia</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Psychometric and cranial CT study in myotonic
dystrophy</article-title>. <source/>Clin Exp Neurol
<year>1984</year>; <volume>20</volume>:
<fpage>161</fpage>–<lpage>167</lpage>.<pub-id pub-id-type="pmid">6568937</pub-id></mixed-citation>
</ref>
<ref id="bibr63-1756286419845567">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Avrahami</surname><given-names>E</given-names></name><name><surname>Katz</surname><given-names>A</given-names></name><name><surname>Bornstein</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>Computed tomographic findings of brain and skull
in myotonic dystrophy</article-title>. <source/>J Neurol Neurosurg
Psychiatry
<year>1987</year>; <volume>50</volume>:
<fpage>435</fpage>–<lpage>438</lpage>.<pub-id pub-id-type="pmid">3585355</pub-id></mixed-citation>
</ref>
<ref id="bibr64-1756286419845567">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Glantz</surname><given-names>R</given-names></name><name><surname>Wright</surname><given-names>R</given-names></name><name><surname>Huckman</surname><given-names>MS</given-names></name><etal>et al</etal></person-group>
<article-title>Central nervous system magnetic resonance
imaging findings in myotonic dystrophy</article-title>. <source/>Arch
Neurol
<year>1988</year>; <volume>45</volume>:
<fpage>36</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">3337674</pub-id></mixed-citation>
</ref>
<ref id="bibr65-1756286419845567">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Romeo</surname><given-names>V</given-names></name><name><surname>Pegoraro</surname><given-names>E</given-names></name><name><surname>Ferrati</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Brain involvement in myotonic dystrophies:
neuroimaging and neuropsychological comparative study in DM1 and
DM2</article-title>. <source/>J Neurol
<year>2010</year>; <volume>257</volume>:
<fpage>1246</fpage>–<lpage>1255</lpage>.<pub-id pub-id-type="pmid">20221771</pub-id></mixed-citation>
</ref>
<ref id="bibr66-1756286419845567">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kornblum</surname><given-names>C</given-names></name><name><surname>Reul</surname><given-names>J</given-names></name><name><surname>Kress</surname><given-names>W</given-names></name><etal>et al</etal></person-group>
<article-title>Cranial magnetic resonance imaging in
genetically proven myotonic dystrophy type 1 and 2</article-title>.
<source/>J Neurol
<year>2004</year>; <volume>251</volume>:
<fpage>710</fpage>–<lpage>714</lpage>.<pub-id pub-id-type="pmid">15311347</pub-id></mixed-citation>
</ref>
<ref id="bibr67-1756286419845567">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Minnerop</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>B</given-names></name><name><surname>Schoene-Bake</surname><given-names>JC</given-names></name><etal>et al</etal></person-group>
<article-title>The brain in myotonic dystrophy 1 and 2:
evidence for a predominant white matter disease</article-title>.
<source/>Brain
<year>2011</year>; <volume>134</volume>:
<fpage>3527</fpage>–<lpage>3543</lpage>.</mixed-citation>
</ref>
<ref id="bibr68-1756286419845567">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Fujimura</surname><given-names>H</given-names></name><name><surname>Soga</surname><given-names>F.</given-names></name></person-group>
<article-title>The fluid-attenuated inversion-recovery pulse sequence in
assessment of central nervous system involvement in myotonic
dystrophy</article-title>. <source/>Neuroradiology
<year>1998</year>; <volume>40</volume>:
<fpage>32</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">9493185</pub-id></mixed-citation>
</ref>
<ref id="bibr69-1756286419845567">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Huber</surname><given-names>S</given-names></name><name><surname>Kissel</surname><given-names>J</given-names></name><name><surname>Shuttleworth</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Magnetic resonance imaging and clinical
correlates of intellectual impairment in myotonic dystrophy</article-title>.
<source/>Arch Neurol
<year>1989</year>; <volume>46</volume>:
<fpage>536</fpage>–<lpage>540</lpage>.<pub-id pub-id-type="pmid">2636847</pub-id></mixed-citation>
</ref>
<ref id="bibr70-1756286419845567">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martinello</surname><given-names>F</given-names></name><name><surname>Piazza</surname><given-names>A</given-names></name><name><surname>Pastorello</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Clinical and neuroimaging study of central
nervous system in congenital myotonic dystrophy</article-title>. <source/>J
Neurol
<year>1999</year>; <volume>246</volume>:
<fpage>186</fpage>–<lpage>192</lpage>.<pub-id pub-id-type="pmid">10323316</pub-id></mixed-citation>
</ref>
<ref id="bibr71-1756286419845567">
<label>71</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ogata</surname><given-names>A</given-names></name><name><surname>Terae</surname><given-names>S</given-names></name><name><surname>Fujita</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Anterior temporal white matter lesions in
myotonic dystrophy with intellectual impairment: an MRI and
neuropathological study</article-title>. <source/>Neuroradiology
<year>1988</year>; <volume>40</volume>:
<fpage>411</fpage>–<lpage>415</lpage>.</mixed-citation>
</ref>
<ref id="bibr72-1756286419845567">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zanigni</surname><given-names>S</given-names></name><name><surname>Evangelisti</surname><given-names>S</given-names></name><name><surname>Giannoccaro</surname><given-names>MP</given-names></name><etal>et al</etal></person-group>
<article-title>Relationship of white and gray matter
abnormalities to clinical and genetic features in myotonic dystrophy type
1</article-title>. <source/>NeuroImage Clin
<year>2016</year>; <volume>11</volume>:
<fpage>678</fpage>–<lpage>685</lpage>.<pub-id pub-id-type="pmid">27330968</pub-id></mixed-citation>
</ref>
<ref id="bibr73-1756286419845567">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Conforti</surname><given-names>R</given-names></name><name><surname>Cristofaro</surname><given-names>M</given-names></name><name><surname>De, Cristofano</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Brain MRI abnormalities in the adult form of
myotonic dystrophy type 1: a longitudinal case series study</article-title>.
<source/>Neuroradiol J
<year>2016</year>; <volume>29</volume>:
<fpage>36</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">26755488</pub-id></mixed-citation>
</ref>
<ref id="bibr74-1756286419845567">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>DeJesus-Hernandez</surname><given-names>M</given-names></name><name><surname>Mackenzie</surname><given-names>IR</given-names></name><name><surname>Boeve</surname><given-names>BF</given-names></name><etal>et al</etal></person-group>
<article-title>Expanded GGGGCC hexanucleotide repeat in
noncoding region of C9ORF72 causes chromosome 9p-linked FTD and
ALS</article-title>. <source/>Neuron
<year>2011</year>; <volume>72</volume>:
<fpage>245</fpage>–<lpage>256</lpage>.<pub-id pub-id-type="pmid">21944778</pub-id></mixed-citation>
</ref>
<ref id="bibr75-1756286419845567">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Di Costanzo</surname><given-names>A</given-names></name><name><surname>Di Salle</surname><given-names>F</given-names></name><name><surname>Santoro</surname><given-names>L</given-names></name><etal>et al</etal></person-group>
<article-title>Brain MRI features of congenital- and adult-form
myotonic dystrophy type 1: case-control study</article-title>.
<source/>Neuromuscul Disord
<year>2002</year>; <volume>12</volume>:
<fpage>476</fpage>–<lpage>483</lpage>.<pub-id pub-id-type="pmid">12031621</pub-id></mixed-citation>
</ref>
<ref id="bibr76-1756286419845567">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bajrami</surname><given-names>A</given-names></name><name><surname>Azman</surname><given-names>F</given-names></name><name><surname>Yayla</surname><given-names>V</given-names></name><etal>et al</etal></person-group>
<article-title>MRI findings and cognitive functions in a small
cohort of myotonic dystrophy type 1: retrospective analyses</article-title>.
<source/>Neuroradiol J
<year>2017</year>; <volume>30</volume>:
<fpage>23</fpage>–<lpage>27</lpage>.<pub-id pub-id-type="pmid">27837184</pub-id></mixed-citation>
</ref>
<ref id="bibr77-1756286419845567">
<label>77</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meola</surname><given-names>G</given-names></name><name><surname>Sansone</surname><given-names>V</given-names></name><name><surname>Perani</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Reduced cerebral blood flow and impaired
visual-spatial function in proximal myotonic myopathy</article-title>.
<source/>Neurology
<year>1999</year>; <volume>53</volume>:
<fpage>1042</fpage>–<lpage>1050</lpage>.<pub-id pub-id-type="pmid">10496264</pub-id></mixed-citation>
</ref>
<ref id="bibr78-1756286419845567">
<label>78</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Okkersen</surname><given-names>K</given-names></name><name><surname>Monckton</surname><given-names>DG</given-names></name><name><surname>Le</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>Brain imaging in myotonic dystrophy type
1</article-title>. <source/>Neurology
<year>2017</year>; <volume>89</volume>:
<fpage>960</fpage>–<lpage>969</lpage>.<pub-id pub-id-type="pmid">28768849</pub-id></mixed-citation>
</ref>
<ref id="bibr79-1756286419845567">
<label>79</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Antonini</surname><given-names>G</given-names></name><name><surname>Mainero</surname><given-names>C</given-names></name><name><surname>Romano</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Cerebral atrophy in myotonic dystrophy: a voxel
based morphometric study</article-title>. <source/>J Neurol Neurosurg
Psychiatry
<year>2004</year>; <volume>75</volume>:
<fpage>1611</fpage>–<lpage>1613</lpage>.<pub-id pub-id-type="pmid">15489397</pub-id></mixed-citation>
</ref>
<ref id="bibr80-1756286419845567">
<label>80</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ota</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><name><surname>Ohya</surname><given-names>Y</given-names></name><etal>et al</etal></person-group>
<article-title>Relationship between diffusion tensor imaging
and brain morphology in patients with myotonic dystrophy</article-title>.
<source/>Neurosci Lett
<year>2006</year>; <volume>407</volume>:
<fpage>234</fpage>–<lpage>239</lpage>.<pub-id pub-id-type="pmid">16978781</pub-id></mixed-citation>
</ref>
<ref id="bibr81-1756286419845567">
<label>81</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schneider-Gold</surname><given-names>C</given-names></name><name><surname>Bellenberg</surname><given-names>B</given-names></name><name><surname>Prehn</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Cortical and subcortical grey and white matter
atrophy in myotonic dystrophies type 1 and 2 is associated with cognitive
impairment, depression and daytime sleepiness</article-title>. <source/>PLoS
One; <volume>10</volume> Epub ahead of print 2015;10(6):e0130352.
DOI: <pub-id pub-id-type="doi">10.1371/journal.pone.0130352</pub-id>.</mixed-citation>
</ref>
<ref id="bibr82-1756286419845567">
<label>82</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sugiyama</surname><given-names>A</given-names></name><name><surname>Sone</surname><given-names>D</given-names></name><name><surname>Sato</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>Brain gray matter structural network in myotonic
dystrophy type 1</article-title>. <source/>PLoS One
<year>2017</year>; <volume>12</volume>:
<fpage>1</fpage>–<lpage>13</lpage>.</mixed-citation>
</ref>
<ref id="bibr83-1756286419845567">
<label>83</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Perrone</surname><given-names>D</given-names></name><name><surname>Valentini</surname><given-names>F</given-names></name><name><surname>Servidio</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Analysis of intermittent heating in a
multi-component turbulent plasma</article-title>. <source/>Eur Phys J
D
<year>2014</year>; <volume>68</volume>:
<fpage>1</fpage>–<lpage>7</lpage>.</mixed-citation>
</ref>
<ref id="bibr84-1756286419845567">
<label>84</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Franc</surname><given-names>DT</given-names></name><name><surname>Muetzel</surname><given-names>RL</given-names></name><name><surname>Robinson</surname><given-names>PR</given-names></name><etal>et al</etal></person-group>
<article-title>Cerebral and muscle MRI abnormalities in
myotonic dystrophy</article-title>. <source/>Neuromuscul Disord
<year>2012</year>; <volume>22</volume>:
<fpage>483</fpage>–<lpage>491</lpage>.<pub-id pub-id-type="pmid">22290140</pub-id></mixed-citation>
</ref>
<ref id="bibr85-1756286419845567">
<label>85</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serra</surname><given-names>L</given-names></name><name><surname>Petrucci</surname><given-names>A</given-names></name><name><surname>Spanò</surname><given-names>B</given-names></name><etal>et al</etal></person-group>
<article-title>How genetics affects the brain to produce
higher-level dysfunctions in myotonic dystrophy type 1</article-title>.
<source/>Funct Neurol
<year>2015</year>; <volume>30</volume>:
<fpage>21</fpage>–<lpage>31</lpage>.<pub-id pub-id-type="pmid">26214024</pub-id></mixed-citation>
</ref>
<ref id="bibr86-1756286419845567">
<label>86</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoo</surname><given-names>WK</given-names></name><name><surname>Park</surname><given-names>YG</given-names></name><name><surname>Choi</surname><given-names>YC</given-names></name><etal>et al</etal></person-group>
<article-title>Cortical thickness and white matter integrity
are associated with CTG expansion size in myotonic dystrophy type
I</article-title>. <source/>Yonsei Med J
<year>2017</year>; <volume>58</volume>:
<fpage>807</fpage>–<lpage>815</lpage>.<pub-id pub-id-type="pmid">28540995</pub-id></mixed-citation>
</ref>
<ref id="bibr87-1756286419845567">
<label>87</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wozniak</surname><given-names>JR</given-names></name><name><surname>Mueller</surname><given-names>BA</given-names></name><name><surname>Ward</surname><given-names>EE</given-names></name><etal>et al</etal></person-group>
<article-title>White matter abnormalities and neurocognitive
correlates in children and adolescents with myotonic dystrophy type 1: a
diffusion tensor imaging study</article-title>. <source/>Neuromuscul
Disord
<year>2011</year>; <volume>21</volume>:
<fpage>89</fpage>–<lpage>96</lpage>.<pub-id pub-id-type="pmid">21169018</pub-id></mixed-citation>
</ref>
<ref id="bibr88-1756286419845567">
<label>88</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wozniak</surname><given-names>JR</given-names></name><name><surname>Mueller</surname><given-names>BA</given-names></name><name><surname>Bell</surname><given-names>CJ</given-names></name><etal>et al</etal></person-group>
<article-title>Diffusion tensor imaging reveals widespread
white matter abnormalities in children and adolescents with myotonic
dystrophy type 1</article-title>. <source/>J Neurol
<year>2013</year>; <volume>260</volume>:
<fpage>1122</fpage>–<lpage>1131</lpage>.<pub-id pub-id-type="pmid">23192171</pub-id></mixed-citation>
</ref>
<ref id="bibr89-1756286419845567">
<label>89</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serra</surname><given-names>L</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><name><surname>Petrucci</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Abnormal functional brain connectivity and
personality traits in myotonic dystrophy type 1</article-title>.
<source/>JAMA Neurol
<year>2014</year>; <volume>71</volume>:
<fpage>603</fpage>–<lpage>611</lpage>.<pub-id pub-id-type="pmid">24664202</pub-id></mixed-citation>
</ref>
<ref id="bibr90-1756286419845567">
<label>90</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wozniak</surname><given-names>JR</given-names></name><name><surname>Mueller</surname><given-names>BA</given-names></name><name><surname>Lim</surname><given-names>KO</given-names></name><etal>et al</etal></person-group>
<article-title>Tractography reveals diffuse white matter
abnormalities in Myotonic Dystrophy Type 1</article-title>. <source/>J Neurol
Sci
<year>2014</year>; <volume>341</volume>:
<fpage>73</fpage>–<lpage>78</lpage>.<pub-id pub-id-type="pmid">24768314</pub-id></mixed-citation>
</ref>
<ref id="bibr91-1756286419845567">
<label>91</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caramia</surname><given-names>F</given-names></name><name><surname>Mainero</surname><given-names>C</given-names></name><name><surname>Gragnani</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Functional MRI changes in the central motor
system in myotonic dystrophy type 1</article-title>. <source/>Magn Reson
Imaging
<year>2010</year>; <volume>28</volume>:
<fpage>226</fpage>–<lpage>234</lpage>.<pub-id pub-id-type="pmid">19695817</pub-id></mixed-citation>
</ref>
<ref id="bibr92-1756286419845567">
<label>92</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Toth</surname><given-names>A</given-names></name><name><surname>Lovadi</surname><given-names>E</given-names></name><name><surname>Komoly</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Cortical involvement during myotonia in myotonic
dystrophy: an fMRI study</article-title>. <source/>Acta Neurol Scand
<year>2015</year>; <volume>132</volume>:
<fpage>65</fpage>–<lpage>72</lpage>.<pub-id pub-id-type="pmid">25630356</pub-id></mixed-citation>
</ref>
<ref id="bibr93-1756286419845567">
<label>93</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Serra</surname><given-names>L</given-names></name><name><surname>Mancini</surname><given-names>M</given-names></name><name><surname>Silvestri</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>Brain connectomics’ modification to clarify
motor and nonmotor features of myotonic dystrophy type 1</article-title>.
<source/>Neural Plast
<year>2016</year>; <fpage>2696085</fpage> Epub ahead of print 25 May 2016. DOI:
<pub-id pub-id-type="doi">10.1155/2016/2696085</pub-id>.<pub-id pub-id-type="pmid">27313901</pub-id></mixed-citation>
</ref>
<ref id="bibr94-1756286419845567">
<label>94</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Seo</surname><given-names>J</given-names></name><name><surname>Cha</surname><given-names>H</given-names></name><etal>et al</etal></person-group>
<article-title>Alterated power spectral density in the
resting-state sensorimotor network in patients with myotonic dystrophy type
1</article-title>. <source/>Sci Rep
<year>2018</year>; <volume>8</volume>: <fpage>987</fpage>.<pub-id pub-id-type="pmid">29343751</pub-id></mixed-citation>
</ref>
<ref id="bibr95-1756286419845567">
<label>95</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fiorelli</surname><given-names>M</given-names></name><name><surname>Duboc</surname><given-names>D</given-names></name><name><surname>Mazoyer</surname><given-names>BM</given-names></name><etal>et al</etal></person-group>
<article-title>Decreased cerebral glucose utilization in
myotonic dystrophy</article-title>. <source/>Neurology
<year>1992</year>; <volume>42</volume>:
<fpage>91</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">1734329</pub-id></mixed-citation>
</ref>
<ref id="bibr96-1756286419845567">
<label>96</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mielke</surname><given-names>R</given-names></name><name><surname>Herholz</surname><given-names>K</given-names></name><name><surname>Fink</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>Positron emission tomography in myotonic
dystrophy</article-title>. <source/>Psychiatry Res
<year>1993</year>; <volume>50</volume>:
<fpage>93</fpage>–<lpage>99</lpage>.<pub-id pub-id-type="pmid">8378492</pub-id></mixed-citation>
</ref>
<ref id="bibr97-1756286419845567">
<label>97</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Annane</surname><given-names>D</given-names></name><name><surname>Fiorelli</surname><given-names>M</given-names></name><name><surname>Mazoyer</surname><given-names>B</given-names></name><etal>et al</etal></person-group>
<article-title>Impaired cerebral glucose metabolism in myotonic
dystrophy: a triplet-size dependent phenomenon</article-title>.
<source/>Neuromuscul Disord
<year>1998</year>; <volume>8</volume>:
<fpage>39</fpage>–<lpage>45</lpage>.<pub-id pub-id-type="pmid">9565989</pub-id></mixed-citation>
</ref>
<ref id="bibr98-1756286419845567">
<label>98</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Romeo</surname><given-names>V</given-names></name><name><surname>Pegoraro</surname><given-names>E</given-names></name><name><surname>Squarzanti</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Retrospective study on PET-SPECT imaging in a
large cohort of myotonic dystrophy type 1 patients</article-title>.
<source/>Neurol Sci
<year>2010</year>; <volume>31</volume>:
<fpage>757</fpage>–<lpage>763</lpage>.<pub-id pub-id-type="pmid">20842397</pub-id></mixed-citation>
</ref>
<ref id="bibr99-1756286419845567">
<label>99</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Renard</surname><given-names>D</given-names></name><name><surname>Collombier</surname><given-names>L</given-names></name><name><surname>Castelli</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>In myotonic dystrophy type 1 reduced FDG-uptake
on FDG-PET is most severe in Brodmann area 8</article-title>. <source/>BMC
Neurol
<year>2016</year>; <volume>16</volume>:
<fpage>1</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">26727957</pub-id></mixed-citation>
</ref>
<ref id="bibr100-1756286419845567">
<label>100</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peric</surname><given-names>S</given-names></name><name><surname>Brajkovic</surname><given-names>L</given-names></name><name><surname>Belanovic</surname><given-names>B</given-names></name><etal>et al</etal></person-group>
<article-title>Brain positron emission tomography in patients
with myotonic dystrophy type 1 and type 2</article-title>. <source/>J Neurol
Sci
<year>2017</year>; <volume>378</volume>:
<fpage>187</fpage>–<lpage>192</lpage>.<pub-id pub-id-type="pmid">28566162</pub-id></mixed-citation>
</ref>
<ref id="bibr101-1756286419845567">
<label>101</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>L</given-names></name><name><surname>Anderson</surname><given-names>T</given-names></name><name><surname>Migneco</surname><given-names>O</given-names></name><etal>et al</etal></person-group>
<article-title>Cerebral abnormalities in myotonic dystrophy.
Cerebral blood flow, magnetic resonance imaging, and neuropsychological
tests</article-title>. <source/>Arch Neurol
<year>1993</year>; <volume>50</volume>:
<fpage>917</fpage>–<lpage>923</lpage>.<pub-id pub-id-type="pmid">8363445</pub-id></mixed-citation>
</ref>
<ref id="bibr102-1756286419845567">
<label>102</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Meola</surname><given-names>G</given-names></name><name><surname>Sansone</surname><given-names>V</given-names></name><name><surname>Perani</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Executive dysfunction and avoidant personality
trait in myotonic dystrophy type 1 (DM-1) and in proximal myotonic myopathy
(PROMM/DM-2)</article-title>. <source/>Neuromuscul Disord
<year>2003</year>; <volume>13</volume>:
<fpage>813</fpage>–<lpage>821</lpage>.<pub-id pub-id-type="pmid">14678804</pub-id></mixed-citation>
</ref>
<ref id="bibr103-1756286419845567">
<label>103</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Takeda</surname><given-names>A</given-names></name><name><surname>Kobayakawa</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Lowered sensitivity to facial emotions in
myotonic dystrophy type 1</article-title>. <source/>J Neurol Sci
<year>2009</year>; <volume>280</volume>:
<fpage>35</fpage>–<lpage>39</lpage>.<pub-id pub-id-type="pmid">19223261</pub-id></mixed-citation>
</ref>
<ref id="bibr104-1756286419845567">
<label>104</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peric</surname><given-names>S</given-names></name><name><surname>Pavlovic</surname><given-names>A</given-names></name><name><surname>Ralic</surname><given-names>V</given-names></name><etal>et al</etal></person-group>
<article-title>Transcranial sonography in patients with
myotonic dystrophy type 1</article-title>. <source/>Muscle Nerve
<year>2014</year>; <volume>50</volume>:
<fpage>278</fpage>–<lpage>282</lpage>.<pub-id pub-id-type="pmid">24395217</pub-id></mixed-citation>
</ref>
<ref id="bibr105-1756286419845567">
<label>105</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Krogias</surname><given-names>C</given-names></name><name><surname>Bellenberg</surname><given-names>B</given-names></name><name><surname>Prehn</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Evaluation of CNS involvement in myotonic
dystrophy type 1 and type 2 by transcranial sonography</article-title>.
<source/>J Neurol
<year>2015</year>; <volume>262</volume>:
<fpage>365</fpage>–<lpage>374</lpage>.<pub-id pub-id-type="pmid">25385052</pub-id></mixed-citation>
</ref>
<ref id="bibr106-1756286419845567">
<label>106</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Udd</surname><given-names>B</given-names></name><name><surname>Meola</surname><given-names>G</given-names></name><name><surname>Krahe</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>Myotonic dystrophy type 2 (DM2) and related
disorders. Report of the 180th ENMC Workshop including guidelines on
diagnostics and management 3-5 December 2010, Naarden, The
Netherlands</article-title>. <source/>Neuromuscul Disord
<year>2011</year>; <volume>21</volume>:
<fpage>443</fpage>–<lpage>450</lpage>.<pub-id pub-id-type="pmid">21543227</pub-id></mixed-citation>
</ref>
<ref id="bibr107-1756286419845567">
<label>107</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hund</surname><given-names>E</given-names></name><name><surname>Jansen</surname><given-names>O</given-names></name><name><surname>Koch</surname><given-names>MC</given-names></name><etal>et al</etal></person-group>
<article-title>Proximal myotonic myopathy with MRI white matter
abnormalities of the brain</article-title>. <source/>Neurology
<year>1997</year>; <volume>48</volume>:
<fpage>33</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">9008490</pub-id></mixed-citation>
</ref>
<ref id="bibr108-1756286419845567">
<label>108</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kassubek</surname><given-names>J</given-names></name><name><surname>Juengling</surname><given-names>FD</given-names></name><name><surname>Hoffmann</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Quantification of brain atrophy in patients with
myotonic dystrophy and proximal myotonic myopathy: a controlled
3-dimensional magnetic resonance imaging study</article-title>.
<source/>Neurosci Lett
<year>2003</year>; <volume>348</volume>:
<fpage>73</fpage>–<lpage>76</lpage>.<pub-id pub-id-type="pmid">12902021</pub-id></mixed-citation>
</ref>
<ref id="bibr109-1756286419845567">
<label>109</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Minnerop</surname><given-names>M</given-names></name><name><surname>Luders</surname><given-names>E</given-names></name><name><surname>Specht</surname><given-names>K</given-names></name><etal>et al</etal></person-group>
<article-title>Grey and white matter loss along cerebral
midline structures in myotonic dystrophy type 2</article-title>. <source/>J
Neurol
<year>2008</year>; <volume>255</volume>:
<fpage>1904</fpage>–<lpage>1909</lpage>.<pub-id pub-id-type="pmid">19224318</pub-id></mixed-citation>
</ref>
<ref id="bibr110-1756286419845567">
<label>110</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Sane</surname><given-names>H</given-names></name><name><surname>Badhe</surname><given-names>P</given-names></name><etal>et al</etal></person-group>
<article-title>A clinical study shows safety and efficacy of
autologous bone marrow mononuclear cell therapy to improve quality of life
in muscular dystrophy patients</article-title>. <source/>Cell
Transplant
<year>2013</year>; <volume>22</volume>(<issue>Suppl. 1</issue>):
<fpage>S127</fpage>–<lpage>S138</lpage>.<pub-id pub-id-type="pmid">24070109</pub-id></mixed-citation>
</ref>
<ref id="bibr111-1756286419845567">
<label>111</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rakocevic-stojanovic</surname><given-names>V</given-names></name><name><surname>Peric</surname><given-names>S</given-names></name><name><surname>Savic-pavicevic</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>Brain sonography insight into the midbrain in
myotonic dystrophy type 2</article-title>. <source/>Muscle Nerve
<year>2016</year>; <volume>53</volume>:
<fpage>700</fpage>–<lpage>704</lpage>.<pub-id pub-id-type="pmid">26425828</pub-id></mixed-citation>
</ref>
<ref id="bibr112-1756286419845567">
<label>112</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Johnston</surname><given-names>T</given-names></name><name><surname>Hor</surname><given-names>K</given-names></name><name><surname>Mah</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Description of Becker muscular dystrophy
cardiomyopathy natural history by cardiac magnetic resonance imaging from
the first to third decades provides insight for cardiac
surveillance</article-title>. <source/>Neuromuscul Disord. Epub
ahead of print 2018; <volume>28</volume>(<issue>2018</issue>):
<fpage>S29</fpage>–<lpage>S146</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.nmd.2018.06.066</pub-id>.</mixed-citation>
</ref>
<ref id="bibr113-1756286419845567">
<label>113</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Diffusion tensor imaging study in Duchenne
muscular dystrophy</article-title>. <source/>Ann Transl Med
<year>2016</year>; <volume>4</volume>: <fpage>109</fpage>.<pub-id pub-id-type="pmid">27127762</pub-id></mixed-citation>
</ref>
<ref id="bibr114-1756286419845567">
<label>114</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Haenggi</surname><given-names>T</given-names></name><name><surname>Fritschy</surname><given-names>JM.</given-names></name></person-group>
<article-title>Role of dystrophin and utrophin for assembly and function of the
dystrophin glycoprotein complex in non-muscle tissue</article-title>.
<source/>Cell Mol Life Sci
<year>2006</year>; <volume>63</volume>:
<fpage>1614</fpage>–<lpage>1631</lpage>.<pub-id pub-id-type="pmid">16710609</pub-id></mixed-citation>
</ref>
<ref id="bibr115-1756286419845567">
<label>115</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Young</surname><given-names>HK</given-names></name><name><surname>Barton</surname><given-names>BA</given-names></name><name><surname>Waisbren</surname><given-names>S</given-names></name><etal>et al</etal></person-group>
<article-title>Cognitive and psychological profile of males
with becker muscular dystrophy</article-title>. <source/>J Child
Neurol
<year>2008</year>; <volume>23</volume>:
<fpage>155</fpage>–<lpage>162</lpage>.<pub-id pub-id-type="pmid">18056690</pub-id></mixed-citation>
</ref>
<ref id="bibr116-1756286419845567">
<label>116</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Waite</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>SC</given-names></name><name><surname>Blake</surname><given-names>DJ.</given-names></name></person-group>
<article-title>The dystrophin-glycoprotein complex in brain development and
disease</article-title>. <source/>Trends Neurosci
<year>2012</year>; <volume>35</volume>:
<fpage>487</fpage>–<lpage>496</lpage>.<pub-id pub-id-type="pmid">22626542</pub-id></mixed-citation>
</ref>
<ref id="bibr117-1756286419845567">
<label>117</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ricotti</surname><given-names>V</given-names></name><name><surname>Mandy</surname><given-names>WPL</given-names></name><name><surname>Scoto</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Neurodevelopmental, emotional, and behavioural
problems in Duchenne muscular dystrophy in relation to underlying dystrophin
gene mutations</article-title>. <source/>Dev Med Child Neurol
<year>2016</year>; <volume>58</volume>:
<fpage>77</fpage>–<lpage>84</lpage>.<pub-id pub-id-type="pmid">26365034</pub-id></mixed-citation>
</ref>
<ref id="bibr118-1756286419845567">
<label>118</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Uchino</surname><given-names>M</given-names></name><name><surname>Teramoto</surname><given-names>H</given-names></name><name><surname>Naoe</surname><given-names>H</given-names></name><etal>et al</etal></person-group>
<article-title>Localisation and characterisation of dystrophin
in the central nervous system of controls and patients with Duchenne
muscular dystrophy</article-title>. <source/>J Neurol Neurosurg
Psychiatry
<year>1994</year>; <volume>57</volume>:
<fpage>426</fpage>–<lpage>429</lpage>.<pub-id pub-id-type="pmid">8163990</pub-id></mixed-citation>
</ref>
<ref id="bibr119-1756286419845567">
<label>119</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hendriksen</surname><given-names>RGF</given-names></name><name><surname>Schipper</surname><given-names>S</given-names></name><name><surname>Hoogland</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>Dystrophin distribution and expression in human
and experimental temporal lobe epilepsy</article-title>. <source/>Front Cell
Neurosci
<year>2016</year>; <volume>10</volume>:
<fpage>1</fpage>–<lpage>14</lpage>.<pub-id pub-id-type="pmid">26858601</pub-id></mixed-citation>
</ref>
<ref id="bibr120-1756286419845567">
<label>120</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Doorenweerd</surname><given-names>N</given-names></name><name><surname>Mahfouz</surname><given-names>A</given-names></name><name><surname>Van Putten</surname><given-names>M</given-names></name><etal>et al</etal></person-group>
<article-title>Timing and localization of human dystrophin
isoform expression provide insights into the cognitive phenotype of Duchenne
muscular dystrophy</article-title>. <source/>Sci Rep
<year>2017</year>; <volume>7</volume>:
<fpage>1</fpage>–<lpage>12</lpage>.<pub-id pub-id-type="pmid">28127051</pub-id></mixed-citation>
</ref>
<ref id="bibr121-1756286419845567">
<label>121</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Nudel</surname><given-names>U</given-names></name><name><surname>Zuk</surname><given-names>D</given-names></name><name><surname>Einat</surname><given-names>P</given-names></name><etal>et al</etal></person-group>
<article-title>Duchenne muscular dystrophy gene product is not
identical in muscle and brain</article-title>. <source/>Nature
<year>1989</year>; <volume>337</volume>:
<fpage>76</fpage>–<lpage>78</lpage>.<pub-id pub-id-type="pmid">2909892</pub-id></mixed-citation>
</ref>
<ref id="bibr122-1756286419845567">
<label>122</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lederfein</surname><given-names>D</given-names></name><name><surname>Levy</surname><given-names>Z</given-names></name><name><surname>Augier</surname><given-names>N</given-names></name><etal>et al</etal></person-group>
<article-title>A 71-kilodalton protein is a major product of
the Duchenne muscular dystrophy gene in brain and other nonmuscle
tissues</article-title>. <source/>Proc Natl Acad Sci USA
<year>1992</year>; <volume>89</volume>:
<fpage>5346</fpage>–<lpage>5350</lpage>.<pub-id pub-id-type="pmid">1319059</pub-id></mixed-citation>
</ref>
<ref id="bibr123-1756286419845567">
<label>123</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Austin</surname><given-names>R</given-names></name><name><surname>Howard</surname><given-names>P</given-names></name><name><surname>D’souza</surname><given-names>V</given-names></name><etal>et al</etal></person-group>
<article-title>Cloning and characterization of alternatively
spliced isoforms of Dp71</article-title>. <source/>Hum Mol Genet
<year>1995</year>; <volume>4</volume>:
<fpage>1475</fpage>–<lpage>1483</lpage>.<pub-id pub-id-type="pmid">8541829</pub-id></mixed-citation>
</ref>
<ref id="bibr124-1756286419845567">
<label>124</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Morris</surname><given-names>GE</given-names></name><name><surname>Simmons</surname><given-names>C</given-names></name><name><surname>Man</surname><given-names>NT.</given-names></name></person-group>
<article-title>Apo-Dystrophins (DP140 and DP71) and Dystrophin-Splicing Isoforms
in Developing Brain</article-title>. <source/>Biochem Biophys Res
Commun
<year>1995</year>; <volume>215</volume>:
<fpage>361</fpage>–<lpage>367</lpage>.<pub-id pub-id-type="pmid">7575614</pub-id></mixed-citation>
</ref>
<ref id="bibr125-1756286419845567">
<label>125</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Duchenne</surname><given-names>G.</given-names></name></person-group>
<source/>Recherches sur la paralysie musculaire pseudohyper trophique, ou
paralysie myo-sclerosique. Archives Générales Médecine
<year>1868</year>; <volume>11</volume>: <fpage>5</fpage>–<lpage>25</lpage>,
179–209, 305–21, 421–43, 552–88.</mixed-citation>
</ref>
<ref id="bibr126-1756286419845567">
<label>126</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Cotton</surname><given-names>S</given-names></name><name><surname>Nicholas</surname><given-names>J</given-names></name><name><surname>Kenneth</surname><given-names>M.</given-names></name></person-group>
<article-title>Intelligence and Duchenne muscular dystrophy: full-scale, verbal,
and performance intelligence quotients</article-title>. <source/>Dev Med
Child Neurol
<year>2001</year>; <volume>43</volume>:
<fpage>497</fpage>–<lpage>501</lpage>.<pub-id pub-id-type="pmid">11463183</pub-id></mixed-citation>
</ref>
<ref id="bibr127-1756286419845567">
<label>127</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hinton</surname><given-names>VJ</given-names></name><name><surname>Vivo</surname><given-names>DCDE</given-names></name><name><surname>Nereo</surname><given-names>NE.</given-names></name></person-group>
<article-title>Selective deficits in verbal working memory associated with a
known genetic etiology: the neuropsychological profile of duchenne muscular
dystrophy NIH Public Access</article-title>. <source/>J Int Neuropsychol
Soc. Jan;7(1):45–54. <year>2001</year>; <volume>7</volume>:
<fpage>45</fpage>–<lpage>54</lpage>.<pub-id pub-id-type="pmid">11253841</pub-id></mixed-citation>
</ref>
<ref id="bibr128-1756286419845567">
<label>128</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hinton</surname><given-names>VJ</given-names></name><name><surname>De Vivo</surname><given-names>DC</given-names></name><name><surname>Fee</surname><given-names>R</given-names></name><etal>et al</etal></person-group>
<article-title>Investigation of poor academic achievement in
children with Duchenne muscular dystrophy</article-title>. <source/>Learn
Disabil Res Pract
<year>2004</year>; <volume>19</volume>:
<fpage>146</fpage>–<lpage>154</lpage>.<pub-id pub-id-type="pmid">17710256</pub-id></mixed-citation>
</ref>
<ref id="bibr129-1756286419845567">
<label>129</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hinton</surname><given-names>VJ</given-names></name><name><surname>Fee</surname><given-names>RJ</given-names></name><name><surname>Goldstein</surname><given-names>EM</given-names></name><etal>et al</etal></person-group>
<article-title>Verbal and memory skills in males with Duchenne
muscular dystrophy</article-title>. <source/>Dev Med Child Neurol
<year>2007</year>; <volume>49</volume>:
<fpage>123</fpage>–<lpage>128</lpage>.<pub-id pub-id-type="pmid">17254000</pub-id></mixed-citation>
</ref>
<ref id="bibr130-1756286419845567">
<label>130</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Billard</surname><given-names>C</given-names></name><name><surname>Gillet</surname><given-names>P</given-names></name><name><surname>Signoret</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Cognitive functions in Duchenne muscular
dystrophy: a reappraisal and comparison with spinal muscular
atrophy</article-title>. <source/>Neuromuscul Disord
<year>1992</year>; <volume>2</volume>:
<fpage>371</fpage>–<lpage>378</lpage>.<pub-id pub-id-type="pmid">1300185</pub-id></mixed-citation>
</ref>
<ref id="bibr131-1756286419845567">
<label>131</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Castles</surname><given-names>A</given-names></name><name><surname>Coltheart</surname><given-names>M.</given-names></name></person-group>
<article-title>Varieties of developmental dyslexia</article-title>.
<source/>Cognition
<year>1993</year>; <volume>47</volume>:
<fpage>149</fpage>–<lpage>180</lpage>.<pub-id pub-id-type="pmid">8324999</pub-id></mixed-citation>
</ref>
<ref id="bibr132-1756286419845567">
<label>132</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dorman</surname><given-names>C</given-names></name><name><surname>Hurley</surname><given-names>A</given-names></name><name><surname>D’Avignon</surname><given-names>J.</given-names></name></person-group>
<article-title>Language and learning disorders of older boys with Duchenne
muscular dystrophy</article-title>. <source/>Dev Med Child Neurol
<year>1998</year>; <volume>30</volume>:
<fpage>316</fpage>–<lpage>327</lpage>.</mixed-citation>
</ref>
<ref id="bibr133-1756286419845567">
<label>133</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pane</surname><given-names>M</given-names></name><name><surname>Messina</surname><given-names>S</given-names></name><name><surname>Bruno</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Duchenne muscular dystrophy and
epilepsy</article-title>. <source/>Neuromuscul Disord
<year>2013</year>; <volume>23</volume>:
<fpage>313</fpage>–<lpage>315</lpage>.<pub-id pub-id-type="pmid">23465656</pub-id></mixed-citation>
</ref>
<ref id="bibr134-1756286419845567">
<label>134</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Banihani</surname><given-names>R</given-names></name><name><surname>Smile</surname><given-names>S</given-names></name><name><surname>Yoon</surname><given-names>G</given-names></name><etal>et al</etal></person-group>
<article-title>Cognitive and neurobehavioral profile in boys
with duchenne muscular dystrophy</article-title>. <source/>J Child
Neurol
<year>2015</year>; <volume>30</volume>:
<fpage>1472</fpage>–<lpage>1482</lpage>.<pub-id pub-id-type="pmid">25660133</pub-id></mixed-citation>
</ref>
<ref id="bibr135-1756286419845567">
<label>135</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>F</given-names></name><name><surname>Muntoni</surname><given-names>F</given-names></name><name><surname>Dubowitz</surname><given-names>V.</given-names></name></person-group>
<article-title>Epilepsy in Duchenne and Becker muscular
dystrophies</article-title>. <source/>Eur J Paediatr Neurol
<year>1997</year>; <volume>1</volume>:
<fpage>115</fpage>–<lpage>119</lpage>.<pub-id pub-id-type="pmid">10728205</pub-id></mixed-citation>
</ref>
<ref id="bibr136-1756286419845567">
<label>136</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Septien</surname><given-names>L</given-names></name><name><surname>Gras</surname><given-names>P</given-names></name><name><surname>Borsotti</surname><given-names>JP</given-names></name><etal>et al</etal></person-group>
<article-title>[Mental development in Duchenne muscular
dystrophy. Correlation of data of the brain scanner]</article-title>.
<source/>Pediatrie
<year>1991</year>; <volume>46</volume>:
<fpage>817</fpage>–<lpage>819</lpage>.<pub-id pub-id-type="pmid">1667037</pub-id></mixed-citation>
</ref>
<ref id="bibr137-1756286419845567">
<label>137</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>M</given-names></name><name><surname>Okuno</surname><given-names>T</given-names></name><name><surname>Honda</surname><given-names>Y</given-names></name><etal>et al</etal></person-group>
<article-title>Central nervous system involvement in
progressive muscular dystrophy</article-title>. <source/>Arch Dis
Child
<year>1980</year>; <volume>55</volume>:
<fpage>589</fpage>–<lpage>594</lpage>.<pub-id pub-id-type="pmid">7436514</pub-id></mixed-citation>
</ref>
<ref id="bibr138-1756286419845567">
<label>138</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Xu</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>D</given-names></name><name><surname>Pratt</surname><given-names>SJP</given-names></name><etal>et al</etal></person-group>
<article-title>Abnormalities in brain structure and
biochemistry associated with mdx mice measured by in vivo MRI and high
resolution localized <sup>1</sup>H MRS</article-title>. <source/>Neuromuscul
Disord
<year>2015</year>; <volume>25</volume>:
<fpage>764</fpage>–<lpage>772</lpage>.<pub-id pub-id-type="pmid">26236031</pub-id></mixed-citation>
</ref>
<ref id="bibr139-1756286419845567">
<label>139</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Doorenweerd</surname><given-names>N</given-names></name><name><surname>Straathof</surname><given-names>CS</given-names></name><name><surname>Dumas</surname><given-names>EM</given-names></name><etal>et al</etal></person-group>
<article-title>Reduced cerebral gray matter and altered white
matter in boys with Duchenne muscular dystrophy</article-title>. <source/>Ann
Neurol
<year>2014</year>; <volume>76</volume>:
<fpage>403</fpage>–<lpage>411</lpage>.<pub-id pub-id-type="pmid">25043804</pub-id></mixed-citation>
</ref>
<ref id="bibr140-1756286419845567">
<label>140</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lv</surname><given-names>SY</given-names></name><name><surname>Zou</surname><given-names>QH</given-names></name><name><surname>Cui</surname><given-names>JL</given-names></name><etal>et al</etal></person-group>
<article-title>Decreased gray matter concentration and local
synchronization of spontaneous activity in the motor cortex in Duchenne
muscular dystrophy</article-title>. <source/>Am J Neuroradiol
<year>2011</year>; <volume>32</volume>:
<fpage>2196</fpage>–<lpage>2200</lpage>.<pub-id pub-id-type="pmid">21960496</pub-id></mixed-citation>
</ref>
<ref id="bibr141-1756286419845567">
<label>141</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bresolin</surname><given-names>N</given-names></name><name><surname>Castelli</surname><given-names>E</given-names></name><name><surname>Comi</surname><given-names>GP</given-names></name><etal>et al</etal></person-group>
<article-title>Cognitive impairment in Duchenne muscular
dystrophy</article-title>. <source/>Neuromuscul Disord
<year>1994</year>; <volume>4</volume>:
<fpage>359</fpage>–<lpage>369</lpage>.<pub-id pub-id-type="pmid">7981593</pub-id></mixed-citation>
</ref>
<ref id="bibr142-1756286419845567">
<label>142</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Pfund</surname><given-names>Z</given-names></name><name><surname>Juhász</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Altered regional brain glucose metabolism in
Duchenne muscular dystrophy: a pet study</article-title>. <source/>Muscle
Nerve
<year>2002</year>; <volume>26</volume>:
<fpage>506</fpage>–<lpage>512</lpage>.<pub-id pub-id-type="pmid">12362416</pub-id></mixed-citation>
</ref>
<ref id="bibr143-1756286419845567">
<label>143</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Rae</surname><given-names>C</given-names></name><name><surname>Scott</surname><given-names>RB</given-names></name><name><surname>Thompson</surname><given-names>CH</given-names></name><etal>et al</etal></person-group>
<article-title>Brain biochemistry in Duchenne muscular
dystrophy: a 1H magnetic resonance and neuropsychological
study</article-title>. <source/>J Neurol Sci
<year>1998</year>; <volume>160</volume>:
<fpage>148</fpage>–<lpage>157</lpage>.<pub-id pub-id-type="pmid">9849797</pub-id></mixed-citation>
</ref>
<ref id="bibr144-1756286419845567">
<label>144</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van der Ploeg</surname><given-names>AT</given-names></name><name><surname>Clemens</surname><given-names>PR</given-names></name><name><surname>Corzo</surname><given-names>D</given-names></name><etal>et al</etal></person-group>
<article-title>A randomized study of alglucosidase alfa in
late-onset Pompe’s disease</article-title>. <source/>N Engl J Med
<year>2010</year>; <volume>362</volume>:
<fpage>1396</fpage>–<lpage>1406</lpage>.<pub-id pub-id-type="pmid">20393176</pub-id></mixed-citation>
</ref>
<ref id="bibr145-1756286419845567">
<label>145</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Winkel</surname><given-names>LPF</given-names></name><name><surname>Hagemans</surname><given-names>MLC</given-names></name><name><surname>Van Doorn</surname><given-names>PA</given-names></name><etal>et al</etal></person-group>
<article-title>The natural course of non-classic Pompe’s
disease; a review of 225 published cases</article-title>. <source/>J
Neurol
<year>2005</year>; <volume>252</volume>:
<fpage>875</fpage>–<lpage>884</lpage>.<pub-id pub-id-type="pmid">16133732</pub-id></mixed-citation>
</ref>
<ref id="bibr146-1756286419845567">
<label>146</label>
<mixed-citation publication-type="journal">
<collab>American Association of Neuromuscular Medicine Electrodiagnostic
Medicine</collab>. <article-title>Diagnostic criteria for late-onset
(childhood and adult) Pompe disease</article-title>. <source/>Muscle
Nerve
<year>2009</year>; <volume>40</volume>:
<fpage>149</fpage>–<lpage>160</lpage>.<pub-id pub-id-type="pmid">19533647</pub-id></mixed-citation>
</ref>
<ref id="bibr147-1756286419845567">
<label>147</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Raben</surname><given-names>N</given-names></name><name><surname>Plotz</surname><given-names>P</given-names></name><name><surname>Byrne</surname><given-names>B.</given-names></name></person-group>
<article-title>Acid a-glucosidase deficiency (glycogenosis type II, Pompe
disease)</article-title>. <source/>Curr Mol Med
<year>2002</year>; <volume>2</volume>:
<fpage>145</fpage>–<lpage>166</lpage>.<pub-id pub-id-type="pmid">11949932</pub-id></mixed-citation>
</ref>
<ref id="bibr148-1756286419845567">
<label>148</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Di Rocco</surname><given-names>M</given-names></name><name><surname>Buzz</surname><given-names>D</given-names></name><name><surname>Tarò</surname><given-names>M</given-names></name></person-group>
<article-title>Glycogen storage disease type II: clinical
overview</article-title>. <source/>Acta Myol
<year>2007</year>; <volume>26</volume>:
<fpage>42</fpage>–<lpage>44</lpage>.<pub-id pub-id-type="pmid">17915568</pub-id></mixed-citation>
</ref>
<ref id="bibr149-1756286419845567">
<label>149</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van der Walt</surname><given-names>J</given-names></name><name><surname>Swash</surname><given-names>M</given-names></name><name><surname>Leake</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>The pattern of involvement of adult-onset acid
maltase deficiency at autopsy</article-title>. <source/>Muscle Nerve
<year>1987</year>; <volume>10</volume>:
<fpage>272</fpage>–<lpage>281</lpage>.<pub-id pub-id-type="pmid">2951596</pub-id></mixed-citation>
</ref>
<ref id="bibr150-1756286419845567">
<label>150</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gambetti</surname><given-names>P</given-names></name><name><surname>Dimauro</surname><given-names>S</given-names></name><name><surname>Baker</surname><given-names>L.</given-names></name></person-group>
<article-title>Nervous system in Pompe’s disease</article-title>. <source/>J
Neuropathology Exp Neurol
<year>1971</year>; <volume>30</volume>:
<fpage>412</fpage>–<lpage>430</lpage>.</mixed-citation>
</ref>
<ref id="bibr151-1756286419845567">
<label>151</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Martin</surname><given-names>JJ</given-names></name><name><surname>de Barsy</surname><given-names>T</given-names></name><name><surname>Van Hoof</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Pompe’s disease: an inborn lysosomal disorder
with storage of glycogen - a study of brain and striated
muscle</article-title>. <source/>Acta Neuropathologica
<year>1973</year>; <volume>23</volume>:
<fpage>229</fpage>–<lpage>244</lpage>.<pub-id pub-id-type="pmid">4511788</pub-id></mixed-citation>
</ref>
<ref id="bibr152-1756286419845567">
<label>152</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>CP</given-names></name><name><surname>Lin</surname><given-names>SP</given-names></name><name><surname>Tzen</surname><given-names>CY</given-names></name><etal>et al</etal></person-group>
<article-title>Detection of a homozygous D645E mutation of the
acid alpha-glucosidase gene and glycogen deposition in tissues in a
second-trimester fetus with infantile glycogen storage disease type
II</article-title>. <source/>Prenat Diagn
<year>2004</year>; <volume>24</volume>:
<fpage>231</fpage>–<lpage>232</lpage>.<pub-id pub-id-type="pmid">15057961</pub-id></mixed-citation>
</ref>
<ref id="bibr153-1756286419845567">
<label>153</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>van den Hout</surname><given-names>HM</given-names></name><name><surname>Hop</surname><given-names>W</given-names></name><name><surname>van Diggelen</surname><given-names>OP</given-names></name><etal>et al</etal></person-group>
<article-title>The natural course of infantile Pompe’s disease:
20 original cases compared with 133 cases from the
literature</article-title>. <source/>Pediatrics
<year>2003</year>; <volume>112</volume>:
<fpage>332</fpage>–<lpage>340</lpage>.<pub-id pub-id-type="pmid">12897283</pub-id></mixed-citation>
</ref>
<ref id="bibr154-1756286419845567">
<label>154</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chien</surname><given-names>Y-H</given-names></name><name><surname>Lee</surname><given-names>N-C</given-names></name><name><surname>Peng</surname><given-names>S-F</given-names></name><etal>et al</etal></person-group>
<article-title>Brain development in infantile-onset Pompe
disease treated by enzyme replacement therapy</article-title>.
<source/>Pediatr Res
<year>2006</year>; <volume>60</volume>:
<fpage>349</fpage>–<lpage>352</lpage>.<pub-id pub-id-type="pmid">16857770</pub-id></mixed-citation>
</ref>
<ref id="bibr155-1756286419845567">
<label>155</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burrow</surname><given-names>TA</given-names></name><name><surname>Bailey</surname><given-names>LA</given-names></name><name><surname>Kinnett</surname><given-names>DG</given-names></name><etal>et al</etal></person-group>
<article-title>Acute progression of neuromuscular findings in
infantile pompe disease</article-title>. <source/>Pediatr Neurol
<year>2010</year>; <volume>42</volume>:
<fpage>455</fpage>–<lpage>458</lpage>.<pub-id pub-id-type="pmid">20472203</pub-id></mixed-citation>
</ref>
<ref id="bibr156-1756286419845567">
<label>156</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ebbink</surname><given-names>BJ</given-names></name><name><surname>Aarsen</surname><given-names>FK</given-names></name><name><surname>Van Gelder</surname><given-names>CM</given-names></name><etal>et al</etal></person-group>
<article-title>Cognitive outcome of patients with classic
infantile Pompe disease receiving enzyme therapy</article-title>.
<source/>Neurology
<year>2012</year>; <volume>78</volume>:
<fpage>1512</fpage>–<lpage>1518</lpage>.<pub-id pub-id-type="pmid">22539577</pub-id></mixed-citation>
</ref>
<ref id="bibr157-1756286419845567">
<label>157</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ebbink</surname><given-names>BJ</given-names></name><name><surname>Poelman</surname><given-names>E</given-names></name><name><surname>Plug</surname><given-names>I</given-names></name><etal>et al</etal></person-group>
<article-title>Cognitive decline in classic infantile Pompe
disease: an underacknowledged challenge</article-title>.
<source/>Neurology
<year>2016</year>; <volume>86</volume>:
<fpage>1260</fpage>–<lpage>1261</lpage>.<pub-id pub-id-type="pmid">26944269</pub-id></mixed-citation>
</ref>
<ref id="bibr158-1756286419845567">
<label>158</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bloomfield</surname><given-names>A</given-names></name><name><surname>Fletcher</surname><given-names>J</given-names></name><name><surname>Hensman</surname><given-names>P</given-names></name><etal>et al</etal></person-group>
<article-title>Rapidly progressive white matter involvement in
early childhood: the expanding phenotype of infantile onset
Pompe?</article-title>
<source/>JIMD Reports
<year>2017</year>; <volume>39</volume>:
<fpage>55</fpage>–<lpage>62</lpage>.<pub-id pub-id-type="pmid">28726123</pub-id></mixed-citation>
</ref>
<ref id="bibr159-1756286419845567">
<label>159</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tan</surname><given-names>QKG</given-names></name><name><surname>Stockton</surname><given-names>DW</given-names></name><name><surname>Pivnick</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Premature pubarche in children with Pompe
disease</article-title>. <source/>J Pediatr
<year>2015</year>; <volume>166</volume>:
<fpage>1075</fpage>–<lpage>1078.e1</lpage>.<pub-id pub-id-type="pmid">25687635</pub-id></mixed-citation>
</ref>
<ref id="bibr160-1756286419845567">
<label>160</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ebbink</surname><given-names>BJ</given-names></name><name><surname>Poelman</surname><given-names>E</given-names></name><name><surname>Aarsen</surname><given-names>FK</given-names></name><etal>et al</etal></person-group>
<article-title>Classic infantile Pompe patients approaching
adulthood: a cohort study on consequences for the brain</article-title>.
<source/>Dev Med Child Neurol
<year>2018</year>; <volume>60</volume>:
<fpage>579</fpage>–<lpage>586</lpage>.<pub-id pub-id-type="pmid">29573408</pub-id></mixed-citation>
</ref>
<ref id="bibr161-1756286419845567">
<label>161</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Borroni</surname><given-names>B</given-names></name><name><surname>Cotelli</surname><given-names>MS</given-names></name><name><surname>Premi</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>The brain in late-onset glycogenosis II: a
structural and functional MRI study</article-title>. <source/>J Inherit Metab
Dis
<year>2013</year>; <volume>36</volume>:
<fpage>989</fpage>–<lpage>995</lpage>.<pub-id pub-id-type="pmid">23609349</pub-id></mixed-citation>
</ref>
<ref id="bibr162-1756286419845567">
<label>162</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brais</surname><given-names>B</given-names></name><name><surname>Rouleau</surname><given-names>G</given-names></name><name><surname>Bouchard</surname><given-names>J</given-names></name><etal>et al</etal></person-group>
<article-title>Oculopharyngeal muscular
dystrophy</article-title>. <source/>Semin Neurol
<year>1999</year>; <volume>19</volume>:
<fpage>56</fpage>–<lpage>99</lpage>.</mixed-citation>
</ref>
<ref id="bibr163-1756286419845567">
<label>163</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brais</surname><given-names>B.</given-names></name></person-group>
<article-title>Oculopharyngeal muscular dystrophy: a polyalanine
myopathy</article-title>. <source/>Curr Neurol Neurosci Rep
<year>2009</year>; <volume>9</volume>:
<fpage>76</fpage>–<lpage>82</lpage>.<pub-id pub-id-type="pmid">19080757</pub-id></mixed-citation>
</ref>
<ref id="bibr164-1756286419845567">
<label>164</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Abu-Baker</surname><given-names>A</given-names></name><name><surname>Rouleau</surname><given-names>GA.</given-names></name></person-group>
<article-title>Oculopharyngeal muscular dystrophy: recent advances in the
understanding of the molecular pathogenic mechanisms and treatment
strategies</article-title>. <source/>Biochim Biophys Acta
<year>2007</year>; <volume>1772</volume>:
<fpage>173</fpage>–<lpage>185</lpage>.<pub-id pub-id-type="pmid">17110089</pub-id></mixed-citation>
</ref>
<ref id="bibr165-1756286419845567">
<label>165</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Linoli</surname><given-names>G</given-names></name><name><surname>Tomelleri</surname><given-names>G</given-names></name><name><surname>Ghezzi</surname><given-names>M.</given-names></name></person-group>
<article-title>Oculopharyngeal muscular dystrophy. Description of a case with
involvement of the central nervous system</article-title>.
<source/>Pathologica
<year>1991</year>; <volume>83</volume>:
<fpage>325</fpage>–<lpage>334</lpage>.<pub-id pub-id-type="pmid">1923632</pub-id></mixed-citation>
</ref>
<ref id="bibr166-1756286419845567">
<label>166</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Blumen</surname><given-names>SC</given-names></name><name><surname>Bouchard</surname><given-names>JP</given-names></name><name><surname>Brais</surname><given-names>B</given-names></name><etal>et al</etal></person-group>
<article-title>Cognitive impairment and reduced life span of
oculopharyngeal muscular dystrophy homozygotes</article-title>.
<source/>Neurology
<year>2009</year>; <volume>73</volume>:
<fpage>596</fpage>–<lpage>601</lpage>.<pub-id pub-id-type="pmid">19704078</pub-id></mixed-citation>
</ref>
<ref id="bibr167-1756286419845567">
<label>167</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dubbioso</surname><given-names>R</given-names></name><name><surname>Moretta</surname><given-names>P</given-names></name><name><surname>Manganelli</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>Executive functions are impaired in heterozygote
patients with oculopharyngeal muscular dystrophy</article-title>. <source/>J
Neurol
<year>2012</year>; <volume>259</volume>:
<fpage>833</fpage>–<lpage>837</lpage>.<pub-id pub-id-type="pmid">21956377</pub-id></mixed-citation>
</ref>
<ref id="bibr168-1756286419845567">
<label>168</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chen</surname><given-names>T</given-names></name><name><surname>Lu</surname><given-names>XH</given-names></name><name><surname>Wang</surname><given-names>HF</given-names></name><etal>et al</etal></person-group>
<article-title>Oculopharyngeal weakness, hypophrenia, deafness,
and impaired vision: a novel autosomal dominant myopathy with rimmed
vacuoles</article-title>. <source/>Chin Med J
<year>2016</year>; <volume>129</volume>:
<fpage>1805</fpage>–<lpage>1810</lpage>.<pub-id pub-id-type="pmid">27453229</pub-id></mixed-citation>
</ref>
<ref id="bibr169-1756286419845567">
<label>169</label>
<mixed-citation publication-type="confproc">
<person-group person-group-type="author"><name><surname>Tawil</surname><given-names>R</given-names></name><name><surname>Van Der Maarel</surname><given-names>S</given-names></name><name><surname>Padberg</surname><given-names>GW</given-names></name><etal>et al</etal></person-group>
<article-title>171st ENMC International Workshop: Standards of
care and management of facioscapulohumeral muscular
dystrophy</article-title>. <conf-name>Neuromuscul Disord</conf-name>
<year>2010</year>; <volume>20</volume>:
<fpage>471</fpage>–<lpage>475</lpage>.</mixed-citation>
</ref>
<ref id="bibr170-1756286419845567">
<label>170</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Fierro</surname><given-names>B</given-names></name><name><surname>Daniele</surname><given-names>O</given-names></name><name><surname>Aloisio</surname><given-names>A</given-names></name><etal>et al</etal></person-group>
<article-title>Evoked potential study in facio-scapulo-humeral
muscular dystrophy</article-title>. <source/>Acta Neurol Scand
<year>1997</year>; <volume>95</volume>:
<fpage>346</fpage>–<lpage>350</lpage>.<pub-id pub-id-type="pmid">9228268</pub-id></mixed-citation>
</ref>
<ref id="bibr171-1756286419845567">
<label>171</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Funakoshi</surname><given-names>M</given-names></name><name><surname>Goto</surname><given-names>K</given-names></name><name><surname>Arahata</surname><given-names>K.</given-names></name></person-group>
<article-title>Epilepsy and mental retardation in a subset of early onset
4q35-facioscapulohumeral muscular dystrophy</article-title>.
<source/>Neurology
<year>1998</year>; <volume>50</volume>:
<fpage>1791</fpage>–<lpage>1794</lpage>.<pub-id pub-id-type="pmid">9633729</pub-id></mixed-citation>
</ref>
<ref id="bibr172-1756286419845567">
<label>172</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Brouwer</surname><given-names>OF</given-names></name><name><surname>Padberg</surname><given-names>GW</given-names></name><name><surname>Bakker</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Early onset facioscapulohumeral muscular
dystrophy</article-title>. <source/>Muscle Nerve
<year>1995</year>; <volume>18</volume>:
<fpage>S67</fpage>–<lpage>S72</lpage>.</mixed-citation>
</ref>
<ref id="bibr173-1756286419845567">
<label>173</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mishra</surname><given-names>SK</given-names></name><name><surname>Currier</surname><given-names>RD</given-names></name><name><surname>Smith</surname><given-names>EE</given-names></name><etal>et al</etal></person-group>
<article-title>Facioscapulohumeral dystrophy associated with
multiple sclerosis</article-title>. <source/>Arch Neurol
<year>1984</year>; <volume>41</volume>:
<fpage>570</fpage>–<lpage>571</lpage>.<pub-id pub-id-type="pmid">6721727</pub-id></mixed-citation>
</ref>
<ref id="bibr174-1756286419845567">
<label>174</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Di Lazzaro</surname><given-names>V</given-names></name><name><surname>Oliviero</surname><given-names>A</given-names></name><name><surname>Pilato</surname><given-names>F</given-names></name><etal>et al</etal></person-group>
<article-title>The physiological basis of transcranial motor
cortex stimulation in conscious humans</article-title>. <source/>Clin
Neurophysiol
<year>2004</year>; <volume>115</volume>:
<fpage>255</fpage>–<lpage>266</lpage>.<pub-id pub-id-type="pmid">14744565</pub-id></mixed-citation>
</ref>
<ref id="bibr175-1756286419845567">
<label>175</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Quarantelli</surname><given-names>M</given-names></name><name><surname>Lanzillo</surname><given-names>R</given-names></name><name><surname>Del Vecchio</surname><given-names>W</given-names></name><etal>et al</etal></person-group>
<article-title>Modifications of brain tissue volumes in
facioscapulohumeral dystrophy</article-title>. <source/>NeuroImage
<year>2006</year>; <volume>32</volume>:
<fpage>1237</fpage>–<lpage>1242</lpage>.<pub-id pub-id-type="pmid">16806975</pub-id></mixed-citation>
</ref>
<ref id="bibr176-1756286419845567">
<label>176</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Carlier</surname><given-names>PG</given-names></name><name><surname>Bertoldi</surname><given-names>D</given-names></name><name><surname>Baligand</surname><given-names>C</given-names></name><etal>et al</etal></person-group>
<article-title>Muscle blood flow and oxygenation measured by
NMR imaging and spectroscopy</article-title>. <source/>NMR Biomed
<year>2006</year>; <volume>19</volume>:
<fpage>954</fpage>–<lpage>967</lpage>.<pub-id pub-id-type="pmid">17075963</pub-id></mixed-citation>
</ref>
<ref id="bibr177-1756286419845567">
<label>177</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Doorenweerd</surname><given-names>N</given-names></name><name><surname>Dumas</surname><given-names>EM</given-names></name><name><surname>Ghariq</surname><given-names>E</given-names></name><etal>et al</etal></person-group>
<article-title>Decreased cerebral perfusion in Duchenne
muscular dystrophy patients</article-title>. <source/>Neuromuscul
Disord
<year>2017</year>; <volume>27</volume>:
<fpage>29</fpage>–<lpage>37</lpage>.<pub-id pub-id-type="pmid">27927595</pub-id></mixed-citation>
</ref>
<ref id="bibr178-1756286419845567">
<label>178</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Angelini</surname><given-names>C.</given-names></name></person-group>
<article-title>Challenges and progress in the diagnosis of Congenital Muscular
Dystrophies</article-title>. <source/>Expert Opinion on Orphan Drugs
<year>2016</year>;
<volume>4</volume>:<fpage>347</fpage>–<lpage>358</lpage>.</mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>